Formulari Ubat ubatan kkm

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY An initial test dose of 0.5 ml822 Iron Dextran 50 mg Fe/ml B03AC06000P3001X B Severe iron deficiency should be given over the Injection X anaemia desired route. For severe iron deficiency anaemia, 1-2 ml Dialysis patients on daily given by deep IM. Dosage is individualized erythropoietin therapy, according to total iron deficit second and third trimester Individualised dosage. pregnancy and post partum ADULT and ELDERLY: Cumulative dose is to be823 Iron Sucrose 100 mg/5 ml B03AC02250P3001X A/KK anaemia patients with iron administered in single doses Injection X deficiency: of 100 - 200 mg of iron 2 - 3 i) who are not responsive to times weekly depending on oral iron therapy Hb level. By IV drip infusion, slow IV injection or directly ii) who may be at risk of into the venous limb of the dialyser. Total cumulative allergic reactions to iron dose: 1000 mg dextran injection i) Induction- Initiate at a824 Isoflurane Liquid N01AB06000L5001X B i) Induction and concentration of 0.5 % X ii) Maintenance of ii) Maintenance- 1 - 2.5 % in anaesthesia oxygen or nitrous oxide mixture. 0.5 - 0.75 % with825 Isoniazid 100 mg Tablet J04AC01000T1001X B i) Tuberculosis oxygen and nitrous oxide for X ii)Tuberculous meningitis Caesarian section826 Isoniazid 400 mg Tablet J04AC01000T1002X B i) Tuberculosis i) & ii) ADULT 5-8mg/kg daily X ii)Tuberculous meningitis (Max 300mg) or 15-20mg/kg biweekly (max 1200mg) Complete heart block (third- degree artrioventricular i) & ii) ADULT 5-8mg/kg daily827 Isoprenaline HCl 0.2 mg/ml C01CA02110P3001 B block) not responding to (Max 300mg) or 15-20mg/kg Injection XX biweekly (max 1200mg) atropine, while waiting for If given as IM: Initially 0.2 mg cardiac pacing (1 ml of 1:5000 solution), followed by 0.02-1 mg Complete heart block (third- depending on clinical degree artrioventricular response. If given as SC: 0.2828 Isoprenaline HCl 1 mg/5 ml C01CA02110P3002 B block) not responding to mg (1 ml of 1:5000 solution), Injection XX followed by 0.15-0.2 mg atropine, while waiting for depending on clinical cardiac pacing response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 151 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response. 2-10 mg/hour IV infusion829 Isosorbide Dinitrate 1 mg/ml C01DA08221P3001 A Treatment for angina pectoris after dilution, higher doses up Injection XX and left ventricular failure to 20 mg/hour may be required C01DA08221T1001X Prophylaxis and treatment i) 30 - 120 mg daily in divided Isosorbide Dinitrate 10 mg X for: doses830 Tablet B i) Angina ii) 40 - 160 mg, up to 240 mg ii) Left ventricular failure if required831 Isosorbide Mononitrate 50 C01DA14221C2001 A Prophylaxis and treatment of 50 mg daily mg SR Capsule XX angina pectoris Initiate at 30 mg for 1st 2-4 days to avoid headache.832 Isosorbide-5-Mononitrate 30 C01DA14221T5001X A Prophylaxis and treatment of Usual dose: 60 mg once angina pectoris daily, may be increased to mg SR Tablet X 120 mg once daily833 Isosorbide-5-Mononitrate 60 C01DA14221T5002X A Prophylaxis and treatment of 60mg once daily, increase to mg SR Tablet X angina pectoris 120 mg daily 0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body Only for treatment of weight per day. After about 4 i) Severe nodulo-cystic acne weeks, therefore, dosage for834 Isotretinoin 10 mg Capsule D10BA01000C1001 A* ii) Acne conglobata the maintenance treatment XX iii) Acne fulminans iv) Severe should be adjusted within the acne vulgaris failing range 0f 0.1-1mg/kg daily to conventional treatment. meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re- starting treatment. 0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; Only for treatment of the maximum recommended dose is 2mg/kg of body i) Severe nodulo-cystic acne weight per day. After about 4 ii) Acne conglobata weeks, therefore, dosage for835 Isotretinoin 20 mg Capsule D10BA01000C1002 A* iii) Acne fulminans the maintenance treatment XX iv) Severe acne vulgaris should be adjusted within the failing conventional treatment range 0f 0.1-1mg/kg daily to WARNING: THIS DRUG IS meet individual need. TERATOGENIC Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re- starting treatment.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 152 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Treatment of gastrointestinal symptoms of functional, non- ulcer dyspepsia (chronic 50 mg 3 times daily before A03FA00110T1001X gastritis) i.e sensation of836 Itopride HCl 50 mg Tablet X A* bloating, early satiety, upper meal abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting i) 200 mg daily for 1 week. If no response after 1 week, continue treatment for Treatment of: another week i) oral and/or oesophageal ii) 100 - 200 mg twice daily837 Itraconazole 10 mg/ml Oral J02AC02000L9901X A* candidiasis for 2 weeks. If no response Solution X ii) fluconazole resistant after 2 weeks, continue and/or oesophageal treatment for another 2 candidiasis weeks. The 400 mg daily dose should not be used for more than 14 days if there are no signs of improvement i) 200 mg once daily for 7 days i) Dermatomycosis including ii) 100 mg daily for 15 days pityriasis versicolor iii) 200 mg twice daily for 7 Itraconazole 100 mg J02AC02000C1001X ii) Oral candidiasis days Capsule X iii) Palmar tinea manus and iv) 200mg twice daily for 1838 A/KK plantar tinea pedis week per month for 2 months iv) Fingernail onychomycosis v) 200 mg twice daily for 1 v) Toenail onychomycosis week per month for 3 months vi) Vulvovaginal candidiasis vi)200 mg morning and evening for 1 day or 200 mg once daily for 3 days i) Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance to beta blockers ii) Treatment of coronary artery disease. Symptomatic839 Ivabradine 5 mg Tablet C01EB17110T1001X A* treatment of chronic stable Initial dose 5 mg twice daily. X angina pectoris in coronary May increase dose after 3-4 artery disease patients with weeks to 7.5 mg twice daily depending on response. normal sinus rhythm. ELDERLY, initial dose 2.5 Ivabradine is indicated: - in mg twice daily and titrate to a patients unable to tolerate or maximum of 7.5 mg twice with a contraindication to the daily use of beta-blockers - or in combination with beta- blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV classUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 153 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY840 Ivabradine 7.5 mg Tablet C01EB17110T1002X with sinus rhythm and whose Initial dose 5 mg twice daily. X A* heart rate is ≥75bpm, in May increase dose after 3-4841 Kanamycin 1 g Injection combination with standard weeks to 7.5 mg twice daily J01GB04183P4001X A* beta-blocker therapy or when depending on response.842 Ketamine 10 mg/ml X B beta- blocker therapy is ELDERLY, initial dose 2.5 Injection B contraindicated or not mg twice daily and titrate to a N01AX03110P3001X tolerated. maximum of 7.5 mg twice843 Ketamine 50 mg/ml X i) Symptomatic treatment of daily Injection chronic stable angina N01AX03110P3002X pectoris in patients with i) ADULT: 1 - 2 g daily IM in 1 X normal sinus rhythm, who - 2 equally divided doses. have a contraindication or CHILD: 30 - 50 mg/kg/day in intolerance to beta blockers 1 - 2 divided doses ii) Treatment of coronary ii) ADULT: 2 g daily IM in 2 artery disease. Symptomatic equally divided doses twice a treatment of chronic stable week or 1 g once daily 3 angina pectoris in coronary days a week artery disease patients with IV Initially, 1-4.5 mg/kg IV, a normal sinus rhythm. dose of 2 mg/kg produces Ivabradine is indicated: - in anesth for 5-10 mins. IM patients unable to tolerate or Initially, 6.5-13 mg/kg IM, a with a contraindication to the dose of 10 mg/kg produces use of beta-blockers - or in anesth for 12-25 mins. combination with beta- IV Initially, 1-4.5 mg/kg IV, a blockers in patients dose of 2 mg/kg produces inadequately controlled with anesthesia for 5-10 mins. IM an optimal beta-blocker dose Initially, 6.5-13 mg/kg IM, a and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is ≥75bpm, in combination with standard beta-blocker therapy or when beta- blocker therapy is contraindicated or not tolerated. i) Treatment of gonorrhoea and neonatal meningitis ii) Treatment of TB patients who require reserved second line drugs but have no pre- existing renal complications Sole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states) Sole anaesthetic for short procedures or induction of anaesthesia in certain typesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 154 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY of patients (e.g in shock dose of 10 mg/kg produces states) anesthesia for 12-25 mins.844 Ketoconazole 2% Shampoo D01AC08000L5201X A/KK Resistant dandruff only Apply twice weekly for 2 - 4 X weeks. Prophylaxis: Once every 1 - 2 weeks i) 200 mg with meal once i) Pityriasis versicolor daily for 10 days Ketoconazole 200 mg J02AB02000T1001X ii) Systemic mycosis (other ii) 200 - 400 mg daily for 4845 Tablet X A/KK skin mycoses) weeks - 6 months iii) Nail infections iii) 200 - 400 mg daily for 6 - 12 months.846 Ketoprofen 2.5% Gel M02AA10000G3001 A As a short term treatment for Apply onto affected areas 2-4 XX traumatic lesions, sprains, times daily up to 10 days. tendinitis, oedema, bruises Ketoprofen 200 mg Slow 200mg in the morning or Release Capsule M01AE03000C2002 Pain and inflammation in evening. Should be taken847 XX A/KK rheumatic disease with food: Take immediately after meals. Treatment of signs & symptoms of arthritis Ketoprofen 30 mg M02AA10000M7001 deformans, periarthritis Transdermal Plaster XX humero-scapularis, tendinitis, Apply 1 plaster to the848 A peritendinitis, sore muscle, affected area twice daily swelling, pain resulting from trauma (eg. contusion, distorsion, sprain). By deep IM into gluteal To be used only in treatment muscle, 50-100 mg every 4 Ketoprofen 50 mg/ml M01AE03000P3001849 Injection XX A* of acute inflammatory hours. Maximum 200 mg in conditions 24 hours for up to 3 days. Child not recommended850 Ketorolac Tromethamine S01BC05239D2001 A i) Ocular itching due to Prophylaxis and reduction of 0.5% Eye drops XX allergic conjunctivitis inflammation and associated ii) Prophylaxis and reduction symptoms following ocular of inflammation and surgery: 1 drop 3 times daily associated symptoms starting 24 hours pre- following ocular surgery operatively and continuing up to 3 weeks post-operatively. ADULT: 60mg as a single851 Ketorolac Tromethamine 30 M01AB15239P3001 A* Short term management of dose via IM inj or 30mg as a mg/ml Injection XX moderate to severe single IV dose. Alternatively, postoperative pain 30mg every 6 hr via IM or IV admin up to a max of 120mg daily. ADULT: 100 mg (50 mg in elderly) daily with food, Labetalol HCl 100 mg increased at intervals of 14 Tablet C07AG01110T1001 Hypertension (including in days to usual dose of 200 mg852 XX B pregnancy) twice daily, up to 800 mg twice daily (3 - 4 divided doses if higher dose). Max: 2.4 g daily ADULT: 100 mg (50 mg in853 Labetalol HCl 200 mg C07AG01110T1002 B Hypertension (including in elderly) daily with food, Tablet XX pregnancy) increased at intervals of 14 days to usual dose of 200 mg twice daily, up to 800 mgUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 155 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY twice daily (3 - 4 divided doses if higher dose). Max: 2.4 g daily ADULT: 20mg injected slowly for at least 2 min, followed by854 Labetalol HCl 5 mg/ml C07AG01110P3001 B Hypertension crisis 40-80mg dose every 10 min, Injection XX if necessary upto 300 mg. Patient should remain supine during and 3 hr after the procedure. Atrophic vaginitis: 1 vaginal tablet daily for 6-12 days followed by a maintenance dose of 1 vaginal tablet for 1- 2 days per week Restoration i) Atrophic vaginitis due to therapy: 1-2 vaginal tablet estrogen deficiency during daily for 6-12 days menopause and post- Administration The vaginal menopause, or as co- tablets should be inserted Lactobacillus acidophilus medication to systemic deeply into the vagina in the 100 million viable cells and G03CC06953T1001 hormone replacement evenings before bedtime.855 estriol 0.03mg vaginal tablet XX A/KK therapy In cases of a very dry vagina, vaginal tablet can be ii) Restoration of the Lactobacillus flora after local moistened with 1 or 2 drops and/or systemic treatment of water before insertion into with anti-infective agents or the vagina. chemotherapeutic agents During menstruation, treatment should be interrupted and resumed afterwards Should not use vaginal douches or rinses during treatment i) ADULT 15 ml twice daily adjusted to patient's need. CHILD 0.5 ml/kg/dose once856 Lactulose 3.35 g/5 ml Liquid A06AD11000L5001X C+ i) Constipation or twice daily X ii) Hepatic encephalopathy ii) 30-50 ml 3-4 times daily, dose adjusted to produce 2-3 soft stools daily. CHILD 1 ml/kg/dose 3-4 times daily ADULT: 150 mg twice daily857 Lamivudine 10 mg/ml Oral J05AF05000L9901X A* HIV infection in combination or 300 mg once daily. Solution X with other antiretroviral INFANT under 1 month: 2 agents mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily Adult: 100 mg once daily. For Management of chronic patients with hepatitis B infection concomitant HIV infection:858 Lamivudine 100 mg Tablet J05AF05000T1001X A* associated with evidence of 300 mg once daily or in 2 X hepatitis B viral replication divided doses. Child: >2 yr: 3 and active liver inflammation mg/kg once daily. Max: 100 mg/day.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 156 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE859 Lamivudine 150 mg Tablet J05AF05000T1002X CATEGORY HIV infection in combination ADULT: 150 mg twice daily860 Lamotrigine 100 mg Tablet X A/KK with other antiretroviral or 300 mg once daily. Lamotrigine 25 mg N03AX09000T1002X A agents INFANT under 1 month: 2 A mg/kg twice daily. CHILD 3861 Dispersible/Chewable X i) Adjunctive or monotherapy month or over: 4 mg/kg twice Tablet N03AX09000T2001X A for partial seizures and daily. Maximum 300 mg daily generalised tonic-clonic Lamotrigine 5 mg X A seizures not satisfactorily i) Up to 200 mg daily in single862 Dispersible/Chewable controlled with other or divided dosage N03AX09000T2002X antiepileptic drugs ii) 25- 200 mg daily Tablet X ii) Prevention of mood episodes in adult 18 years 25 mg daily - 50 mg twice863 Lamotrigine 50 mg Tablet N03AX09000T1001X and above with bipolar daily X disorder, predominately by a) Add-on therapy in patients preventing depressive not taking Valproate: week 1 episodes and 2: 2 mg/kg/day twice Add-on therapy in intractable daily, week 3 and 4: 5 partial seizures mg/kg/day twice daily. Maintenance: 5 - 15 Management of seizures in mg/kg/day twice daily b) Add- children aged 2 - 12 years on therapy in patients taking Valproate or other anti- i) Adjunctive or monotherapy epileptic drugs, week 1 and for partial seizures and 2: 0.2 mg/kg/day as a single generalised tonic-clonic dose (children less than 25 seizures not satisfactorily kg may take 5 mg on controlled with other alternate days), week 3 and antiepileptic drugs 4: 0.5 mg/kg/day as a single ii) Prevention of mood dose. Maintenance dose: 1 - episodes in adult 18 years 5 mg/kg/day once daily or and above with bipolar twice daily disorder, predominately by preventing depressive i) Up to 200 mg daily in single episodes or divided dosage ii) 25- 200 mg dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 157 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 30mg daily in the morning for up to 4 weeks (duodenal ulcer) or up to 8 weeks (gastric ulcer). Maintenance: 15mg/day. ii) 30mg OD in the morning for up to 8 weeks if not864 Lansoprazole 30 mg Tablet A02BC03000T1001X A* i) Peptic ulcer disease healed. Maintenance: 15mg X ii) Reflux oesophagitis OD. iii) Zollinger-Ellison iii) Initially 60mg OM & adjust Syndrome as required. Daily doses iv) For eradication of >120mg should be given in 2 Helicobacter pylori in divided doses. combination with antibiotic iv) 30 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily , amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1-2 weeks865 Lanthanum Carbonate V03AE03130T2004X A* Phosphate binding agent for Initial: 750 to 1500 mg/day in 1000mg Chewable Tablet X the treatment of divided doses with meals, hyperphosphataemia in then titrate in increments of dialysis patients with 750 mg/day at intervals of 2 sustained hypercalcaemia of to 3 weeks. Maintenance: more than three months and 1500-3000 mg/day in divided secondary doses. Max: 3750 g/day hyperparathyroidism Hurler and Hurler-Scheie forms of 0.58 mg/kg of body weight Mucopolysaccharidosis I administered once-weekly as866 Laronidase 2.9 mg/5ml A16AB05000P3001X A* (MPS I) and for patients with an intravenous infusion Injection X the Scheie form who have moderate to severe symptoms i) 5,000 iu/m2 for 10 days during induction, 10,000 iu/m2 also used with high867 L-Asparaginase 10,000 IU L01XX02000P3001X A* i) Acute lymphoblastic dose methotrexate rescue in Injection X leukemia consolidation phase of acute ii) Non-hodgkin's lymphoma lymphoblastic leukemia ii) CHILD: 5,000 - 25,000 iu/m2 per dose depending on protocol For reduction of Intraocular Pressure (IOP) in patients Latanoprost 0.005% and S01ED51990D2004 A* with Open-angle Glaucoma 1 drop in the affected eye(s)868 timolol maleate 0.5% eye XX (OAG) and Ocular once daily Hypertension (OH) who are drops insufficiently responsive to topical beta-blocker. The recommended dosage is Reduction of elevated one drop (1.5 µg) in the Latanoprost 0.005% Eye S01EE01000D2001X intraocular pressure in affected eye(s) once daily in869 Drops X A* patients with open-angle the evening. If more than one glaucoma topical ophthalmic drug is being used, the drugs shouldUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 158 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY be administered at least five870 Leflunomide 10 mg Tablet L04AA13000T1001X A* i) Persistent active (5) minutes apart X rheumatoid arthritis Loading dose: 100 mg once ii) Active psoriatic arthritis daily for 3 days. Maintenance: 10-20 mg once871 Leflunomide 20 mg Tablet L04AA13000T1002X A* i) Persistent active daily X rheumatoid arthritis Loading dose: 100 mg once ii) Active psoriatic arthritis daily for 3 days. Maintenance: 10-20 mg once In combination with daily. Recommended starting dose: dexamethesone is indicated 25 mg once daily on days 1 to 21 of repeated 28 day872 Lenalidomide 10 mg L04AX04000C1002X A* for the treatment of multiple cycle with dexamethasone 40 Capsule X myeloma patients who have mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each received at least one prior 28 day cycle for the first 4 therapy cycles of therapy, thereafter dexamethasone 40 mg once In combination with daily on day 1 to 4 every 28 day cycle dexamethesone is indicated Recommended starting dose: 25 mg once daily on days 1873 Lenalidomide 15 mg L04AX04000C1003X A* for the treatment of multiple to 21 of repeated 28 day Capsule X myeloma patients who have cycle with dexamethasone 40 mg once daily on days 1 to 4, received at least one prior 9 to 12 and 17 to 20 of each therapy 28 day cycle for the first 4 cycles of therapy, thereafter In combination with dexamethasone 40 mg once daily on day 1 to 4 every 28 dexamethesone is indicated day cycle Recommended starting dose:874 Lenalidomide 25 mg L04AX04000C1004X A* for the treatment of multiple 25 mg once daily on days 1 Capsule X myeloma patients who have to 21 of repeated 28 day cycle with dexamethasone 40 received at least one prior mg once daily on days 1 to 4, therapy 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 In combination with cycles of therapy, thereafter dexamethasone 40 mg once dexamethesone is indicated daily on day 1 to 4 every 28 day cycle875 Lenalidomide 5 mg Capsule L04AX04000C1001X A* for the treatment of multiple X myeloma patients who have Recommended starting dose: 25 mg once daily on days 1 received at least one prior to 21 of repeated 28 day therapy cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycleUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 159 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE L02BG04000T1001X CATEGORY i) Treatment of hormone876 Letrozole 2.5 mg Tablet responsive metastatic or 2.5 mg once daily X A* locally advance breast Leucovorin Calcium V03AF03390T1001X A cancer after failure of 15 mg every 6 hours for the877 (Calcium Folinate) 15 mg A tamoxifen next 48 - 72 hours X ii) Adjunct for node positive i) 200mg/m2 by slow IV Tablet A postmenopausal women with injection over a minimum 3 V03AF03237P3001X early breast cancer (positive minutes, followed by 5- Leucovorin Calcium X A* or unknown oestrogen or Fluorouracil or 20mg/m2 IV878 (Calcium Folinate) 3 mg positive progesterone followed by 5-Fluorouracil. In V03AF03237P3002X receptor status / receptor both cases, treatment is Injection X status) who have received 5 repeated daily for 5 days; years of adjuvant tamoxifen may repeat at 4-week Leucovorin Calcium L02AE02122P5002X therapy intervals for 2 courses then879 (Calcium Folinate) 50 mg X Treatment of folic acid 4- to 5-week intervals antagonist overdose ii) 15 mg (approximately Injection 10mg/m2) every 6 hours for i) Biochemical modulator for 10 doses, starting 24 hours880 Leuprolide Acetate 11.25 5-Fluorouracil in the after the beginning of the mg Injection treatment of colorectal methotrexate infusion cancer iii) Up to 1 mg daily ii) As rescue for high dose i) 200mg/m2 by slow IV methotrexate injection over a minimum 3 iii) Megaloblastic anaemias minutes, followed by 5- due to deficiency of folic acid Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In i) Biochemical modulator for both cases, treatment is 5-Fluorouracil in the repeated daily for 5 days; treatment of colorectal may repeat at 4-week cancer intervals for 2 courses then ii) As rescue for high dose 4- to 5-week intervals methotrexate ii) 15 mg (approximately iii) Gestational trophoblastic 10mg/m2) every 6 hours for disease 10 doses, starting 24 hours after the beginning of the i) Endometriosis methotrexate infusion ii) Hormonal therapy in iii) 6 - 12 mg exactly 30 hours advanced prostate cancer after each dose of methotrexate. In EMA-CO regime for high risk gestational trophoblastic disease, use 30 mg IM 11.25 mg every 3 monthsUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 160 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY881 Leuprolide Acetate 3.75 mg L02AE02122P5001X A* i) Endometriosis i) 3.75 mg monthly for 3 - 6 Injection X ii) Hormonal therapy in months advanced prostate cancer ii) 3.75 mg IM or SC injection monthly i) ADULTS and ADOLESCENT (from 16 years): Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 i) Monotherapy therapy in the week. Dose can be further treatment of partial onset increased by 250 mg twice seizures with or without daily every 2 weeks secondary generalization in depending upon the clinical patients from age 16 years of response. Max: 1500 mg age with newly diagnosed twice daily. epilepsy ii) ADULT more than 18 ii) Adjunctive treatment in years and ADOLESCENT partial onset seizures with or (12 to 17 years) more than or Levetiracetam 100 mg/ml N03AX14000P3001X without secondary equal to 50 kg: Initially 500 Injection X generalization in adults and mg twice daily may be882 A* children from 4 years of age increased up to 1500 mg with epilepsy; juvenile twice daily. Dose changes myoclonic epilepsy and can be made in 500 mg twice idiopathic generalized tonic daily increments or clonic epilepsy from 12 years decrements 2 to 4 weekly. of age. To be initiated when CHILD (4 to 11 years) and conventional IV antiepileptic ADOLESCENT (12 to 17 drugs failed to achieve years) less than 50 kg : control, or oral form is Initially 10 mg/kg twice daily, temporarily not feasible in may be increased up to 30 seizure emergencies mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose CHILD: 4-11 years and883 Levetiracetam 100 mg/ml N03AX14000L9901X A* As adjunctive therapy in the adolescent (12-17 years) less Oral Solution X treatment of partial onset than 50 kg: Initially 10 mg/kg seizures with or without twice daily, may be increased secondary generalization in up to 30 mg/kg twice daily. adults and children from 4 Dose changes should not years of age with epilepsy exceed increments or decrements of 10 mg/kg two times daily twice weeklyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 161 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE N03AX14000T1001X CATEGORY884 Levetiracetam 250 mg i) Monotherapy therapy in the i) Monotherapy ADULTS and Tablet X A* treatment of partial onset ADOLESCENT (from 16 seizures with or without years): Starting dose: 250 mg885 Levetiracetam 500 mg N03AX14000T1002X A* secondary generalization in twice daily, Increase dose to Tablet X patients from age 16 years of 500 mg twice daily after 2 age with newly diagnosed week. Dose can be further epilepsy increased by 250 mg twice ii) Adjunctive treatment in daily every 2 week partial onset seizures with or depending upon the clinical without secondary response. Max: 1500 mg generalization in adults and twice daily. children from 4 years of age ii) ADULT more than 18 with epilepsy; juvenile years and ADOLESCENT myoclonic epilepsy and (12-17 years) more than or idiopathic generalized tonic equal to 50 kg: Initially 500 clonic epilepsy from 12 years mg twice daily may be of age increased up to 1500 mg twice daily. Dose changes i) Monotherapy therapy in the can be made in 500 mg twice treatment of partial onset daily increments or seizures with or without decrements 2-4 weekly. secondary generalization in CHILD (4-11 years) and patients from age 16 years of ADOLESCENT (12-17 years) age with newly diagnosed less than 50 kg : Initially 10 epilepsy mg/kg twice daily, may be ii) Adjunctive treatment in increased up to 30 mg/kg partial onset seizures with or twice daily. Dose changes without secondary should not exceed generalization in adults and increments or decrements of children from 4 years of age 10 mg/kg twice daily every 2 with epilepsy; juvenile weeks. CHILD more than or myoclonic epilepsy and equal to 50 kg: Adult dose idiopathic generalized tonic clonic epilepsy from 12 years i) Monotherapy ADULTS and of age ADOLESCENT (from 16 years) : Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kgUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 162 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY twice daily. Dose changes Production of local or should not exceed increments or decrements of886 Levobupivacaine 5mg/ml N01BB10110P3001X A regional anesthesia for 10 mg/kg twice daily every 2 Injection X surgery and obstetrics, and weeks. CHILD more than or for postoperative pain equal to 50 kg: Adult dose management Surgical anesthesia: Lumber epidural: 10 - 20 ml (50 - 150 Symptomatic treatment of mg), caesarean section: 15 - allergic rhinitis (including 30 ml (75 - 150 mg),887 Levocetirizine R06AE09110T1001X A* persistent allergic rhinitis) intrathecal: 3 ml (15 mg), and chronic idopathic peripheral nerve block: 1 - 40 Dihydrochloride 5 mg Tablet X ml, ilioinguinal/iliohypogastric block. CHILD : 0.25 - 0.5 urticaria ml/kg (1.25-2.5 mg/kg) Levodopa 100 mg and N04BA02977T4001X A* Parkinson's Disease Children above 12 years and888 Benserazide 25 mg X adults: 5 mg orally once daily (Swallow whole, do not Dispersible Tablet chew/crush).889 Levodopa 100 mg and N04BA02000T1001X B Parkinson's disease Initially 1 cap tds. Max initial Carbidopa 25 mg Tablet X dose: 6 caps/day. Patients previously on immediate- Levodopa 100 mg, N04BA02977C1001 B Parkinson's Disease release890 Benserazide 25 mg HBS XX Levodopa/Benserazide preparations: Initially dose capsule should substitute every 100mg of Levodopa with 1 controlled-released cap, given at same dosage frequency as before. Increase every 2-3 days. Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previously being taken Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 163 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY The optimum daily dosage891 Levodopa 100 mg, N04BA03977T1002X A* Idiopathic Parkinson's must be determined by Carbidopa 25 mg and X disease careful titration of levodopa in Entacapone 200 mg Tablet each patient. The daily dose should preferably be892 Levodopa 150 mg, N04BA03977T1003X A* Idiopathic Parkinson's optimised using 1 of the 4 Carbidopa 37.5 mg and X disease available tablet strengths Entacapone 200 mg Tablet (50/12.5/200mg, 100/25/200mg,Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapo ne). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equals carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg. The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapo ne). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the 164 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY maximum dose, for the893 Levodopa 200 mg, N04BA02977T1001X B Parkinson's Disease strengths of 50/12.5/200 mg, Benserazide 50 mg Tablet X 100/25/200 mg and 150/37.5/200 mg, is 10894 Levodopa 200 mg, N04BA03977T1004X A* Idiopathic Parkinson's tablets/day. Ten (10) tablets Carbidopa 50 mg & X disease of the strength 150/37.5/200 Entacapone 200 mg Tablet mg equals carbidopa 375 mg/day. Therefore, using aUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg. Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapo ne). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equals carbidopa 375 mg/day. Therefore, using a 165 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY maximum recommended895 Levodopa 250 mg and N04BA02000T1002X B Parkinson's disease daily dose of carbidopa 375 Carbidopa 25 mg Tablet X mg, the maximum daily dose of 200/50/200 mg is 7 tablets896 Levodopa 50 mg, N04BA03977T1001X A* Idiopathic Parkinson's per day. The maximum total Carbidopa 12.5 mg & X disease daily levodopa dose Entacapone 200 mg Tablet administered should not exceed 1500 mg.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previous being taken The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapo ne). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equals carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg. 166 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY897 Levofloxacin 250 mg Tablet J01MA12000T1001X A* Community acquired 500 mg daily for 7 - 14 days X pneumonia898 Levofloxacin 500 mg J01MA12000P3001X A* Community Acquired 500 mg daily for 7 - 14 days Injection X Pneumonia899 Levofloxacin 500 mg Tablet J01MA12000T1002X A* Community acquired 500 mg daily for 7 - 14 days X pneumonia900 Levonorgestrel 1.5 mg G03AC03000T1001 A* Emergency contraception 1.5 mg as a single dose as Tablet XX within 72 hours of soon as possible after coitus unprotected sexual [preferably within 12 hours intercourse for the female but no later than after 72 victim of sexual violence to hours] prevent unwanted pregnancy Levonorgestrel 150 mcg G03AA07954T1001X C+ Contraception 1 tablet daily for 21 days from901 and Ethinyloestradiol 30 X first day of the cycle, followed mcg Tablet by 7 tab free days i) & ii):One unit intrauterine device to be inserted into the uterine cavity within 7 days of the onset of menstruation or i) Contraception (Initial immediately after first902 Levonorgestrel 52 mg G02BA03000P1001 A* release rate of 20 mcg/24 trimester abortion. Intrauterine System XX hours). Postpartum insertion should ii) Idiopathic menorrhagia be postponed until 6 weeks after delivery.Can be inserted at any time of amenorrheic woman. One unit IUD is effective for 5 years Start at low dose and increase at 2-4 weeks interval. Adult: Initially, 50- 100 mcg/day may increase by 25-50 mcg at approximately 3 to 4 weeks intervals until the thyroid903 Levothyroxine Sodium 100 H03AA01520T1001X B Hypothyroidism deficiency is corrected. mcg Tablet X Maintenance: 100-200 mcg/day. CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12 years: 4 - 5 mcg/kg/day; more than 12 years: 2 -3 mcg/kg/day Start at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg.904 Levothyroxine Sodium 25 H03AA01152T1003X B Hypothyroidism ii) Prophylaxis of relapse mcg Tablet X after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 167 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY905 Levothyroxine Sodium 50 H03AA01520T1002X Hypothyroidism 200mcg/day. CHILDREN mcg Tablet X B Initially 12.5-50mcg/day, Used for painless Maintenance: 100-906 Lidocaine 25mg and N01BB52974G1001 A venepunctures, radial artery 150mcg/m2 body surface Prilocaine 25mg Cream XX A* cannulations before area extradural/spinal and other iv) Concomitant907 Lidocaine Medicated N01BB02110M6001 regional blocks in children supplementation during anti- Plaster 5% w/w XX above 1 year old and adults. thyroid drug treatment of Also used in chronic renal hyperthyroidism: 50-100mcg failure patients for insertion of v) Suppression therapy in A-V fistulas and shunts for thyroid cancer: 150-300mcg haemodialysis. Start at low dose and Indicated for the symptomatic increase at 2-4 weeks relief of neuropathic pain interval. Usual recommended associated with previous dose for herpes zoster infection (post- i) Treatment of benign herpetic neuralgia, PHN). euthyroid goitre: 75-200mcg. Restrictions: ii) Prophylaxis of relapse i) For elderly patients with after surgery for euthyroid polymedication status whom goitre: 75-200mcg certain treatment was iii) Substitution therapy in contraindicated or not hypothyroidism: ADULT tolerated. Initially, 25-50mcg/day. Maintenance: 100- 200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100- 150mcg/m2 body surface area iv) Concomitant supplementation during anti- thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer: 150-300mcg Apply a thick layer under occlusive dressing at least 1 hour before the procedure 1 patch /day (Adults & elderly. Cover the painful area once daily for up to 12 hr w/in 24-hr period. Subsequent plaster-free interval: At least 12 hr. Not more than 3 plasters should be used at the same time)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 168 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY ii) Prescribed by pain specialist only. For surface anaesthesia in908 Lignocaine 10 % w/w Spray N01BB02110A4001X B dental practice, in Spray to affected part X otorhinolaryngology and paracentesis Lignocaine 2 % with N01BB52974P3001X B For local anaesthesia By infiltration: 0.5 - 1 ml; not909 Adrenaline (1:80,000) X including infiltration, nerve to exceed 7 mg/kg body and plexus blocks weight Injection Use for endotracheal tubes and instruments, painful procedures in the ear, nose and throat, burns, wounds, Apply to affected area 10910 Lignocaine 2% Jelly N01BB02110G4001 B abrasions, lacerations; mins before catheterization, XX catheterisation of the male etc and female urethra and for symptomatic treatment of cystitis and urethritis911 Lignocaine 2% Viscous N01BB02110L5001X A For post-tonsilectomy, sore As 2% soln: For pain: 300 mg Solution X throat, dumping syndrome, rinsed and ejected for mouth hiccough, reflux vomiting, and throat pain; or gargled painful lesions of the mouth, and swallowed if necessary cardiospasm, instrumentation for pharyngeal pain. Not to of the respiratory and be used more frequently than digestive tract every 3 hr. Max (topical oral soln): 2.4 g/day. Adult Male Instil 20 mL slowly into the urethra until it reaches external sphincter, proximal to the prostrate. Subsequently, apply compression at the corona To provide local anaesthesia for several mins. Fill the and lubrication during length of the urethra w/ the catheterization, exploration remaining gel. Sounding912 Lignocaine 2% with N01BB52974G3001 B by sound and other procedure or cytoscopy Instill Chlorhexidine 0.05% Gel XX endourethral operations and 40 mL (in 3-4 portions) into examinations, cytoscopy and the insertion area then allow symptomatic treatment of 5-10 mins for anaesth to take painful cystitis and urethritis effect. Adult Female Prior to urological procedure, instill 5- 10 mL in small portions to fill the whole urethra & allow anaesth to take effect in 3-5 mins.Childn <12 yr Up to 6 mg/kg. For anaesthesia of mucous Bronchoscopy, 2 - 3 ml with N01BB02110L5002X membranes of the suitable spray; biopsy in X oropharyngeal, tracheal and mouth, 3 - 4 ml with suitable913 Lignocaine 4 % Solution B bronchial areas eg. in spray or swab (with laryngoscopy and adrenaline if necessary); bronchoscopy maximum 7.5 ml 50-100 mg IV as a bolus,914 Lignocaine HCl (Lidocaine) C01BB01110P3002X B Ventricular tachycardia and repeated after 5 minutes if 100 mg/ml Injection X ventricullar fibrillation. To be necessary. Maintenance : 1-4 diluted before use mg/min by IV infusion under ECG monitoringUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 169 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Local anesthesia: ADULT Maximum: 100 mg; CHILD Local anesth by infiltration IV Maximum: 3 mg/kg Cardiac regional anesthesia and arrhythmias: ADULT 50-100915 Lignocaine HCl (Lidocaine) N01BB02110P3001X B nerve block. Emergency mg IV. Maximum: 200-300 2% Injection X management of ventricular mg/hour; CHILD Loading arrhythmias particularly after dose: 0.5-1 mg/kg IV myocardial infarction and repeated if necessary up to cardiac surgery 3-5 mg/kg followed by a continuous infusion of 10-50 mcg/kg/min Ventricular tachycardia and 50-100 mg IV as a bolus, ventricullar fibrillation. To be repeated after 5 minutes if916 Lignocaine HCl (Lidocaine) C01BB01110P3001X B diluted before use necessary. Maintenance : 1-4 20 mg/ml Injection X mg/min by IV infusion under ECG monitoring According to patient’s weight and nature of procedures, maximum 200mg. For most N01BB02110P3002X obstetric procedures, the X Local or regional anaesthesia preparation is diluted to917 Lignocaine HCl 1% Injection C+ for episiotomy repairs 0.5%, which gives the maximum effect with the least toxicity. [lignocaine 1%, 1 part and normal saline or sterile distilled water, 1 part] Preparation of nasal mucosa for surgery (eg. Cautery to Lignocaine HCl 5% and N01BB02984A4101X A* Little’s area), aid the Adults and children over 12918 Phenylephrine HCl 0.5% X treatment of acute nose years: 5 squirts per nostril. bleeds and removal of Children: 8 to 12 years 3 Nasal Spray foreign bodies from the nose, squirts per nostril, 4 to 8 topical anaesthesia of the years 2 squirts per nostril, 2 pharynx prior to direct or to 4 years 1 squirt per nostril. indirect laryngoscopy, topical Doses are to be administered anaesthesia and local once only. vasoconstriction prior to endoscopy of the upper airways Lignocaine, Aluminium C05AX03931G5001 A/KK Anorectal pain, pruritis, Apply once or twice daily. Not919 Acetate, Zinc Oxide and XX inflammation and irritation for prolonged use Hydrocortisone Ointment920 Lignocaine, Aluminium C05AX03931S2001X B Anorectal pain, pruritis, 1 suppository to be used Acetate, Zinc Oxide and X inflammation and irritation once or twice daily. Not for Hydrocortisone Suppository prolonged use FUKKM restriction: As add- on therapy for patient who921 Linagliptin 5 mg tablet A10BH05000T1001X A* failed therapy and/or Adults: 5 mg once daily. X contraindicated/unable to When linagliptin is added to tolerate metformin and/or metformin, the dose of sulphonylurea. metformin should be maintained and linagliptin  Management of administered concomitantly. diabetes in patients with renal failure where metformin/sulphonylurea isUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 170 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY922 Linezolid 2 mg/ml Injection J01XX08000P3001X contraindicated/untolerat ADULT: 600 mg twice daily X A* ed and elderly with for 10 - 14 days. CHILD: 10923 Linezolid 20 mg/ml A* multiple co morbidities mg/kg 3 times daily. Suspension J01XX08000L8001X A* that always experience PREMATURE NEONATES X C hypoglycemia with other less than 7 days: 10 mg/kg924 Linezolid 600 mg Tablet A antidiabetic. Not to be twice daily J01XX08000T1001X used in diabetic patient CHILD: 10 mg/kg 3 times925 Liquid Paraffin X B whose HBA1c is more daily. PREMATURE than 9%. NEONATES less than 7926 Lithium Carbonate 300 mg A06AA01000L5001X A days: 10 mg/kg twice daily Tablet X MRSA patient with severe ADULT: Above 12 years 600 sepsis requiring intensive mg every 12 hours for 10-14927 Loperamide 2 mg Capsule N05AN01121T1001X care and not clinically days. CHILD: 10 mg/kg 3 X responding to vancomycin times daily. PREMATURE928 Lopinavir 100 mg and NEONATES less than 7 Ritonavir 25 mg Tablet A07DA03110C1001 MRSA patients with severe days: 10 mg/kg twice daily XX sepsis requiring intensive ADULT 10-30 ml daily at care and not clinically night but should not be taken J05AE06964T1002X responding to vancomycin immediately before going to X bed. CHILD not MRSA patient with severe recommended sepsis requiring intensive care and not clinically Dose depends on the responding to vancomycin. preparation used. Doses should be adjusted to Constipation produce a serum-lithium concentration of 0.4-1 i) Prophylaxis and treatment mmol/l. of acute mania and hypomania episodes Acute diarrhoea: ADULT: 4 ii) Prophylaxis of manic mg stat, followed by 2 mg depression in bipolar illness after each unformed stool (up or bipolar depression and to 5 days). Usual 6- 8 mg recurrent depression daily. Max: 16 mg daily. Chronic diarrhoea: Initially 4- Adjunct to rehydration in 8 mg daily in divided doses, acute diarrhoea in adult also adjust according to response. in chronic diarrhoea in adult Max: 16 mg daily Adult: (Therapy-naive As second line protease patients) 400/100 mg bd or inhibitor if intolerant to 800/200 mg once daily; indinavir/ ritonavir as part of (Therapy-experienced HAART regimen. patients): 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 171 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Adult: (Therapy-naive patients) 400/100 mg bd or 800/200 mg once daily; (Therapy-experienced929 Lopinavir 200 mg and J05AE06964T1001X A As second line protease patients): 400/100 mg bd. Ritonavir 50 mg Tablet X inhibitor if intolerant to Concomitant therapy indinavir/ ritonavir as part of (efavirenz, nevirapine, HAART regimen amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose. Tab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg once daily. Therapy-experienced patients 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, Management of patients with amprenavir, fosamprenavir or asymptomatic and nelfinavir) 400/100 mg bd.930 Lopinavir 80mg/Ritonavir J05AE06964L9901X A symptomatic (early or Can be used w/ no dose 20mg (per ml) Oral Solution X advanced) HIV Infection with adjustment. Childn >40 kg or CD4 cell counts <50 cubic w/ BSA >1.4 m2 Adult dose. mm Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15 kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg.931 Loratadine 1 mg/ml Syrup R06AX13000L9001X A Allergic rhinitis, chronic ADULT and CHILD over 6 X urticaria and other allergic years: 10 mg once daily. dermatological disorders CHILD 2 - 6 years: 5 mg once daily R06AX13000T1001X ADULT and CHILD over 6 X Allergic rhinitis and allergic years 10 mg once daily.932 Loratadine 10 mg Tablet B dermatoses CHILD 2 - 6 years: 5 mg once daily933 Loratadine 5 mg and R01BA52988T1001X A/KK For treatment of allergic ADULT and CHILD over 12 Pseudoephedrine Sulphate X rhinitis and allergic years 1 tablet twice daily 120 mg Tablet dermatoses934 Lorazepam 1 mg Tablet N05BA06000T1001X A/KK i) Severe anxiety i) 1 - 4 mg increase to 10 mg X ii) Insomnia daily in divided doses. ELDERLY (or delibitated) half adult dose ii) 1 - 2 mg at bedtime Not recommended in childrenUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 172 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Hypertension: Usual starting and maintenance dose: 50 mg once daily. Maximum increasing the dose to 100935 Losartan 50 mg Tablet C09CA01500T1001X A/KK Patients intolerant of ACE mg once daily. Patients with X inhibitors, only in the intravascular volume- treatment of depletion starting dose of 25 i) Hypertensive patient with mg once daily. Renal left ventricular hypertrophy protection in Type 2 diabetic ii) Hypertension in diabetics patients with proteinuria and with proteinuria or hypertension, starting dose: nephropathy 50 mg once daily, may be increased to 100 mg once daily based on blood pressure response Fixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure936 Losartan Potassium 100 mg C09DA01935T1004X A* Hypertension in patients who remain uncontrolled after & Hydrochlorothiazide 25 X cannot tolerate ACE about 3 weeks of mg Tablet inhibitors because of cough, combination therapy with hypertensive patient with left losartan & HCTZ 50/12.5mg. ventricular hypertrophy Max: 1 tab of losartan & HCTZ 100/25mg once daily or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily, may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 173 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Fixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure remain uncontrolled after937 Losartan Potassium 100 mg C09DA01935T1003X A* Hypertension in patients who about 3 weeks of and Hydrochlorothiazide X combination therapy with cannot tolerate ACE losartan & HCTZ 50/12.5mg. 12.5 mg Tablet inhibitors because of cough, Max: 1 tab of losartan & HCTZ 100/25mg once daily hypertensive patient with left ventricular hypertrophy or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily, may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily. Patients intolerant of ACE inhibitors, only in the treatment of:938 Losartan Potassium 100 mg C09CA01500T1002X A/KK i) Hypertensive patient with Usual starting dose: 50 mg left ventricular hypertrophy once daily. May be increased Tablet X ii) Hypertension in diabetics to 100 mg once daily. with proteinuria or nephropathy Hypertension in patients who 1 tablet once daily, may939 Losartan Potassium 50 mg C09DA01935T1001X A/KK cannot tolerate ACE increase to maximum dose and Hydrochlorothiazide X inhibitors because of cough, losartan 100 mg/ 12.5 mg Tablet hypertensive patient with left hydrochlorothiazide 25 mg ventricular hypertrophy once daily940 Magnesium Sulphate 45% D11AX05183G6001 C Inflammatory skin conditions Apply under dressing Paste XX such as boils and carbuncles i) Mild hypomagnesemia (ADULT): 1gm magnesium sulphate (8mEq) IM every 6941 Magnesium Sulphate 50% B05XA05183P3001X C i) Treatment and prophylaxis hours for 4 doses. Severe Injection X of acute hypomagnesaemia hypomagnesemia (ADULT): ii) Prevention and treatment 0.25 g/kg IM over 4 hours. of life-threatening seizures in Alternative dose of 5g may the treatment of toxemias of be given by slow intravenous pregnancy (pre-eclampsia infusion over 3 hours and eclampsia) ii) Toxemia of pregnancy: An initial intravenous dose of 4gm of magnesium sulphate is recommended. Followed by an intramuscular dose ofUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 174 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY 4-5gm into each buttock. This may be followed by a dose of 4-5gm into alternate buttocks every 4 hours as needed. Alternatively, the initial dose IV dose may be followed by an infusion of 1-2gm/hr942 Magnesium Trisilicate A02AA10912L2101X C Heartburn, dyspepsia 10-20 ml 3-4 times daily Mixture X before meals ADULT 1-2 tablet to be943 Magnesium Trisilicate A02AA10912T1001X C Heartburn, dyspepsia chewed up to 6 times a day Tablet X before meals. CHILD over 6 years one tablet to be taken 3-4 times a day As a buffering agent for reconstituting didanosine944 Magnesium, Aluminium V07AB00900L8001X C powder for oral DDI should be mixed with Hydroxide and Simethicone X administration so as to water and diluted with the Suspension prevent acid degradation of appropriate dose of antacids didanosine which is used for to a final concentration of 10 the treatment of paediatric mg per ml patients (more than 6 months old) with symptomatic HIV infection Wet hair, apply shampoo and945 Malathion 1 % Shampoo P03AX03000L5201X C+ Lice infestation work up lather. Leave for 15 X minutes and rinse, comb. Repeat if necessary after 7 - 9 days 0.25- 2 g/kg IV of a 15% to946 Mannitol 10% Injection (10 B05BC01000P3001X A Cerebral oedema 25% solution over 30-60 g/100 ml) X minutes. Safety and efficacy not established in children under 12 years of age 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60947 Mannitol 20% Injection (20 B05BC01000P3002X A Cerebral oedema minutes. Safety and efficacy g/100 ml) X not established in children under 12 years of age For active immunization The vaccine should be against measles and rubella reconstituted only with the in infants, children, diluent supplied (sterile water adolescents and young for injection) using a sterile adults at risk. Immunization syringe and needle. With of susceptible non-pregnant gentle shaking the dried cake adolescent and adult females is easily dissolved. After Measles and Rubella Virus is indicated if certain reconstitution the vaccines948 Vaccine Live, Attenuated J07BD52963P4002X C precautions are observed. should be used immediately. (Freeze-dried) 10 doses/vial X The vaccine can be safely A single dose of 0.5ml should and effectively given be administered by deep SC simultaneously with DTP, DT, injection into the anterolateral TT, Td, BCG, Polio Vaccine aspect of upper thigh in (OPV and IPV), Haemophilus infants and upper arm in influenza type B, Hepatitis B, older children. If the vaccines Yellow fever vaccine and is not used immediately then vitamin A supplementation. it should be stored in the darkUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 175 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY949 Measle's Vaccine Injection J07BD01000P4001X Prophylaxis against measles at 20C and 80C for no longer (10 doses) X C+ and to prevent development than 6 hours. C+ of infection (if given within 72 Measles, Mumps and J07BD52963P4001X B hours of contact) By SC or IM injection, 0.5 ml950 Rubella (MMR) Vaccine X B For immunisation of children as a single dose at 12 - 15 B against measles, mumps and months of age Injection (Single Dose) A03AA04110T1002X rubella X B Irritable bowel syndrome Subcutaneous or by951 Mebeverine HCl 135 mg Nausea and vomiting of intramuscular injection, 0.5 Tablet R06AE55919T1001X A pregnancy ml X952 Meclozine HCl 25 mg and B Peripheral neuropathies 135 mg 3 times daily Pyridoxine 50 mg Tablet M09AX00000T1001 XX B i) Secondary amenorrhoea 1 - 2 tablet 2 - 3 times daily in953 Mecobalamin 500 mcg A ii) Abnormal uterine bleeding severe cases Tablet G03DA02122T1002 due to hormonal imbalance XX B 1 tablet 3 times daily. The954 Medroxyprogesterone Breast carcinoma, dosage should be adjusted Acetate 10 mg Tablet L02AB02122T1002X B endometrial carcinoma, renal according to age of patient X carcinoma and severity of symptoms955 Medroxyprogesterone i) 5-10 mg daily for 5-10 days Acetate 100 mg Tablet G03DA02122T1001 i) Secondary amenorrhoea started anytime during cycle XX ii) Abnormal uterine bleeding ii) 5-10 mg daily for 5-10956 Medroxyprogesterone due to hormonal imbalance days on day 16-21 of Acetate 5 mg Tablet G03AC06122P3001 menstrual cycle. Optimum XX Prevention of pregnancy and secretory transformation 10957 Medroxyprogesterone to provide long term mg daily for 10 days from day Acetate 50 mg/ml Injection L02AB02122T1001X contraception 16 of the cycle X Breast carcinoma,958 Medroxyprogesterone endometrial carcinoma, renal 200-500 mg orally daily Acetate 500 mg Tablet M01AG01000C1001 carcinoma XX i) 5-10 mg daily for 5-10 days959 Mefenamic Acid 250 mg Mild to moderate pain started anytime during cycle Capsule M01AG01000T1001 ii) 5-10 mg daily for 5-10 XX Mild to moderate pain days on day 16-21 of960 Mefenamic Acid 250 mg menstrual cycle. Optimum Tablet secretory transformation 10 mg daily for 10 days from day 16 of the cycle 150mg to be administered once every 3 month 200-500 mg orally daily ADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritis ADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritisUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 176 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Treatment of malaria: ADULT and CHILD 25 mg/kg usually given over 2-3 days. Prophylaxis of malaria:961 Mefloquine HCl 250 mg P01BC02110T1001X A* For multi-drug resistant ADULT 250 mg once a week. Tablet X cases of malaria only CHILD over 5 kg : 5 mg/kg once a week; prophylaxis should start 1-3 weeks before departure and continue for 4 weeks after last exposure i) Initially 7.5 mg daily. May Only for patients not be increased to 15 mg daily responding to other NSAIDs ii) initially 15 mg daily. May M01AC06000T1001962 Meloxicam 7.5 mg Tablet XX A/KK in the treatment of be reduced to 7.5 mg daily. i) painful osteoarthritis Maximum 15 mg daily. Child ii) rheumatoid arthritis under 12 years not recommended i) Multiple myeloma i) 8 - 10 mg/m2 for 4 days963 Melphalan 2 mg Tablet L01AA03000T1001X A ii) Neuroblastoma, every 4 weeks X rhabdomyosarcoma ii) 10 - 35 mg/m2 once every iii) Recurrent neuroblastoma month For dose regimes, (palliative) refer to protocols964 Melphalan 50 mg Injection L01AA03000P4001X B High dose conditioning 200 mg/ m2 IV infusions in X therapy for stem cell divided doses for Day 1 to transplantation in multiple day 3 followed by IV myeloma infusions of autologous stem cells Adult Initially 5 mg/day on the As monotherapy or as 1st week, 5mg twice a day on the 2nd week, then 15 Memantine HCI 10 mg N06DX01110T1001X adjunctive therapy with mg/day (10mg in the morning Tablet X cholinesterase inhibitors for and 5mg in the evening) on965 A* the symptomatic treatment of the 3rd week. From the 4th patients with moderate to week on, continue treatment severe Alzheimer's disease. with maintenance dose of 20 mg/day (10mg twice a day). Max: 20 mg/day. Adult Initially 5 mg/day on the 1st week, 5mg twice a day on As monotherapy or as the 2nd week, then 15 adjunctive therapy with mg/day (10mg in the morning966 Memantine HCl 20 mg N06DX01110T1002X A* cholinesterase inhibitors for and 5mg in the evening) on Tablet X the symptomatic treatment of the 3rd week. From the 4th patients with moderate to week on, continue treatment severe Alzheimer's disease. with maintenance dose of 20 mg/day (10mg twice a day). Max: 20 mg/day. Immunisation against meningococcal diseases967 Meningococcal A, C, Y, W J07AH04000P4001X B caused by Neisseria Prophylaxis: 0.5 ml 135 Vaccine Injection X meningitis Group A, Group C, intramuscular injection. Group Y or Group W-135 Menotrophin 150 IU Treatment of infertility where clomifene has fail or968 Injection (Follicle G03GA02954P4002 A* stimulation of follicle growth SC or IM injection according Stimulating Hormone 150 XX as part of an assisted to patients response IU and Luteinizing Hormone 150 IU)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 177 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY reproductive technology (ART) Treatment of infertility where Menotrophin 75 IU Injection clomifene has fail or969 (Follicle Stimulating G03GA02954P4001 A* stimulation of follicle growth SC or IM Injection according Hormone 75 IU and XX as part of an assisted to patient's response Luteinizing Hormone 75 IU) reproductive technology (ART) The recommended initial dose of MENOPUR is 75-150 IU daily. The subsequent dosing should be adjusted Menotrophin, Highly Anovulation in women who according to individual have been unresponsive to patient response. Purified 75 IU Injection G03GA02954P4003 A* treatment with clomiphene Adjustments in dose should970 (Follicle Stimulating XX citrate or stimulation of follicle not be made more frequently growth as part of an assisted than every 7 days. The Hormone 75 IU and Luteinizing Hormone 75 IU) reproductive technology recommended dose (ART) increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU.971 Menthol 1.6% in Industrial R01AX30000A9901X C Decongestion of the upper As directed for local use Methylated Spirit Inhalation X respiratory tract Adult: Single site in the jaw: Mepivacaine HCl 2% with N01BB53974P3001X B For local anaesthesia 36 mg (1.8ml). Entire oral972 Adrenaline (1:100,000) X including infiltration and cavity: 180 mg (9 ml). Max: nerve blocks 400 mg (20 ml) per single Injection dental procedure For dental local anaesthesia Adult: Single site in the jaw: including infiltration and 54 mg (1.8 ml). Entire oral973 Mepivacaine HCl 3% N01BB03110P3001X B nerve blocks on patients in cavity: 270 mg (9 ml). Max: Injection X whom adrenalin might be 400 mg (13.3 ml) per single contraindicated dental procedure Leukaemia adults: 2.5mg/kg or 80-00mg/m2 p.o per day, given as a single dose. To be974 Mercaptopurine 50 mg L01BB02000T1001X A i) Langerhan's cell increased at the end of 4 Tablet X histocytosis weeks, If necessary, up to ii) Acute lymphoblastic 5mg/kg p.o per day. leukaemia Maintainance dosage are iii) Acute promyelocytic 1.5mg/kg -2.5mg/kg p.o per leukaemia APML day Children age 5 and older: (maintenance) Induction: 2.5mg/kg/day p.o once daily. Maintanance dose: 1.5mg/kg -2.5mg.kg p.o once daily or 70- 100mg/m2 p.o once daily.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 178 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i. Emperical treatment for presume infections in975 Meropenem 1 g Injection J01DH02000P4002X A* patients (adult and children) ADULT: 0.5g - 1g 8 hourly X with febrile neutropenia, used CHILD: (aged 3 months and as monotherapy or in over): 10-40mg/kg 8 hourly, if combination with anti-virals body weight over 50kg, adult or antifungal agent dosage should be used ii. Septicaemia iii. Serious infections in renal impaired patients i. Emperical treatment for presume infections in patients (adult and children)976 Meropenem 500 mg J01DH02000P4001X A* with febrile neutropenia, used ADULT: 0.5g - 1g 8 hourly Injection X as monotherapy or in CHILD: (aged 3 months and combination with anti-virals over): 10-40mg/kg 8 hourly, if or antifungal agent body weight over 50kg, adult ii. Septicaemia dosage should be used iii. Serious infections in renal impaired patients Ulcerative colitis: 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after977 Mesalazine 1 g Suppository A07EC02259S2002X A Inflammatory bowel disease 2 weeks of therapy. To X of ulcerative colitis and Crohn's disease. achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended Ulcerative colitis: 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after978 Mesalazine 250 mg A07EC02259S2001X A Inflammatory bowel disease 2 weeks of therapy. To Suppository X of ulcerative colitis and achieve maximum benefit, it Crohn's disease. is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended ADULT: 250 - 500 mg 3 - 4979 Mesalazine 250mg MR A07EC02259T1001X A Inflammatory bowel disease times daily for 3 - 6 weeks. Tablet X of ulcerative colitis and CHILD up 2 years with Crohn's disease. Crohn's disease: 20 - 30 mg/daily in divided dosesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 179 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Inflammatory bowel disease ADULT: 250 - 500 mg 3 - 4 of ulcerative colitis and times daily for 3 - 6 weeks.980 Mesalazine 500mg MR A07EC02259T1002X A Crohn's disease. CHILD up 2 years with Tablet X Crohn's disease: 20 - 30 mg/daily in divided doses981 Mesalazine 6.67% w/w A07EC02259G2001 A Inflammatory bowel disease 60 ml (4g) at bedtime, Enema XX of ulcerative colitis and retained overnight, Crohn's disease. approximately 8 hours IV injection at a dosage of 20% of the corresponding oxazaphosphorine dose at982 Mesna 100 mg/ml Injection V03AF01520P3001X A For prevention of urotoxic the times 0 hour X effects of oxazaphosphorines (concurrently with the e.g. ifosfamide and oxazaphosphorine), 4 hours cyclophosphamide and 8 hours thereafter. CHILD: Dose given at greater frequency (e.g. 6 times) and a shorter intervals (e.g. 3 hours) Initial dose:1.25 mg/250 mg As second-line therapy when ORALLY once daily; titrate in diet, exercise and initial increments of 1.25 mg/250 Metformin 500 mg and A10BD02926T1001X B treatment with sulphonylurea mg per day every 2983 Glibenclamide 2.5 mg X or metformin do not result in weeks,2.5 mg/500 mg to 5 adequate glycemic control in mg/500 mg ORALLY twice Tablet patients with type 2 diabetes daily; titrate in increments of mellitus 5 mg/500 mg up to MAX 20 mg/2000 mg once daily Initial dose:1.25 mg/250 mg As second-line therapy when ORALLY once daily; titrate in diet, exercise and initial increments of 1.25 mg/250 treatment with sulphonylurea mg per day every 2984 Metformin 500 mg and A10BD02926T1002X B or metformin do not result in weeks,2.5 mg/500 mg to 5 Glibenclamide 5 mg Tablet X adequate glycemic control in mg/500 mg ORALLY twice patients with type 2 diabetes daily; titrate in increments of mellitus 5 mg/500 mg up to MAX 20 mg/2000 mg once daily985 Metformin HCl 500 mg A10BA02110T5001X A/KK Diabetes mellitus who 500 mg once daily. Maximum Extended Release Tablet X experienced gastrointestinal dose 2000 mg once daily side effects with normal with evening meal metformin Initial: 500mg orally twice Metformin HCl 500 mg A10BA02110T1001X daily with food. Maintenance: Tablet X Titrate in 500mg increments986 B Diabetes mellitus weekly, doses up to 2000 mg daily may be divided into 2 equal doses.987 Metformin HCl 750 mg A10BA02110T5003X A/KK Diabetes mellitus who 500 mg once daily. Maximum Extended Release Tablet X experienced gastrointestinal dose 2000 mg once daily side effects with normal with evening meal metformin Initial 10-20mg per day, increasing by 10-20mg per988 Methadone 5mg/ml Syrup N07BC02110L9001X A/KK Detoxification treatment of day until there are no signs of X narcotic addiction withdrawal or intoxication. Usual dose 40-60mg/dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 180 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 50 mg/m2 once every 3 i) Solid tumours weeks in combination with other drugs (for this dose,989 Methotrexate 1000mg L01BA01520P3005X A ii) Gestational trophoblastic use the 50 mg preparation) Injection X disease ii) 50 mg IV Day 1, 3, 5, 9 iii) Acute leukaemias, every 3 weeks. For high risk gestational trophoblastic lymphomas disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. i) ADULT: 20 mg/m2 weekly. CHILD: 20 - 30 mg/m2 weekly according to protocol ii) Relapsed acute lymphoblastic leukaemia (ALL): 100 mg/m2/day for 5 days 6 weekly according to990 Methotrexate 2.5 mg Tablet L01BA01000T1001X A i) Acute lymphoblastic protocol X leukaemia and acute iii) Dose used by dermatologist: 5 - 25 mg promyelocytic leukemia weekly. Liver biopsy after (maintenance) cumulative dose of 1.5 gram ii) Extensive plaque and repeat liver biopsy with psoriasis, erythrodermic additional gram received. psoriasis, pustular psoriasis, Maximum cumulative dose is Reiter's syndrome, 4 gram. Monitor full blood connective tissue disease count (FBC), renal and liver function iv) Rheumatoid arthritis, psoriatic arthropathy: dose used by rheumatologist: 2.5 mg/week orally starting dose, increasing to 7.5 - 20 mg/weeklyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 181 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 50 mg/m2 once every 2 - 3 i) Solid tumours weeks in combination with ii) Gestational trophoblastic other drugs ii) 50 mg IV Day 1, 3, 5, 9 disease every 3 weeks. For high risk iii) Acute gestational trophoblastic991 Methotrexate 50 mg L01BA01520P3001X A leukaemia/lymphomas iv) disease, use 100 mg/m2 as Injection X Rheumatoid arthritis, part of EMA-CO regime iii) High dose regimes: 500 - psoriatic arthropathy, 3000 mg/m2 per dose may be used, employing the 500 severe/erythrodermic mg preparations. CHILD: Central nervous system psoriasis prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. The 500 mg strength is not for intrathecal (IT) use. Dosage for intrathecal treatment and prophylaxis in leukaemia: less than 1 year: 5 mg, 1 - 2 years: 7.5 mg, 2 - 3 years: 10 mg, more than 3 years: 12.5 mg. IT preparation must be clearly stated/verified. ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE iv) Dose used by rheumatologist: 10 - 15 mg IM injection or oral weekly. Dose used by dermatologist: 10 - 25 mg IM injection weeklyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 182 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY i) 50 mg/m2 once every 3 weeks in combination with other drugs (for this dose, use the 50 mg preparation) ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute i) Solid tumours leukaemia 2 gm/m2 over 24 ii) Gestational trophoblastic hours with folinic acid rescue,992 Methotrexate 500 mg/20 ml L01BA01520P3002X A disease 3 doses for B-cell lineage. 4 Injection X iii) Acute leukaemias, doses for T-lineage all every lymphomas 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. THE 500 MG STRENGTH IS NOT FOR INTRATHECAL USE Apply 0.1% lotion to area to D05AD02000L6001X Repigmenting agent in vitiligo be exposed to the UVA light ( X993 Methoxsalen 1% Lotion A in conjuction with controlled need to dilute the 1% lotion doses of UVA or sunlight to 0.1% lotion, otherwise the skin will burn) 0.2 - 0.6 mg/kg/body weight. For repigmentation of larger994 Methoxsalen 10 mg D05BA02000C1001 A Protection before exposure to lesions (greater than 6 cm Capsule XX sunlight, psoriasis and vitiligo sq): 20 mg/day 2 hours before exposure. Take with food or milk Treatment of anaemia Non Erythropoiesis associated with chronic renal Stimulating Agent (ESA)- failure in the following treated patients: 0.6 mcg/kg, circumstances: once every two weeks (IV or Methoxy Polyethylene i) Patients who require 2 or SC). When the Hb is >11g/dl, more subcutaneous administration can be995 Glycol-epoetin Beta 100 B03XA03000P5001X A* erythropoietin injections per reduced to once monthly mcg/0.3 ml Injection in X week and need to travel to using the dose equal to twice Prefilled Syringe obtain the injections. the previous two weekly ii) Patients who are on high dose. ESA-treated patients: doses of subcutaneous 120-360 mcg once monthlyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 183 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY erythropoietin injections eg. or 60-180 mcg every two 6000 units or more per time weeks. and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue. Treatment of anaemia associated with chronic renal failure in the following Methoxy Polyethylene circumstances: Non Erythropoiesis Glycol-epoetin Beta 120 B03XA03000P5005X i) Patients who require 2 or Stimulating Agent (ESA)-996 mcg/0.3 ml Injection in X A* more subcutaneous treated patients: 0.6 mcg/kg, erythropoietin injections per once every two weeks (IV or Prefilled Syringe week and need to travel to SC). When the Hb is >11g/dl, obtain the injections. administration can be ii) Patients who are on high reduced to once monthly doses of subcutaneous using the dose equal to twice erythropoietin injections eg. the previous two weekly 6000 units or more per time dose. ESA-treated patients: and require more than 1 120-360 mcg once monthly injection of conventional or 60-180 mcg every two erythropoietin per time. weeks. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue. Treatment of anaemia associated with chronic renal failure in the following circumstances: Methoxy Polyethylene i) Patients who require 2 or Non Erythropoiesis more subcutaneous Stimulating Agent (ESA)-997 Glycol-epoetin Beta 150 B03XA03000P5006X A* erythropoietin injections per treated patients: 0.6 mcg/kg, mcg/0.3 ml Injection in X week and need to travel to once every two weeks (IV or obtain the injections. SC). When the Hb is >11g/dl, Prefilled Syringe ii) Patients who are on high administration can be doses of subcutaneous reduced to once monthly erythropoietin injections eg. using the dose equal to twice 6000 units or more per time the previous two weekly and require more than 1 dose. ESA-treated patients : injection of conventional 120-360 mcg once monthly erythropoietin per time. or 60-180 mcg every two iii) Patients who require 2 or weeks more erythropoietin injections per week and where compliance is an issueUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 184 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE B03XA03000P5007X CATEGORY Methoxy Polyethylene Treatment of anaemia Non Erythropoiesis X A* associated with chronic renal Stimulating Agent (ESA)-998 Glycol-epoetin Beta 200 failure in the following treated patients: 0.6 mcg/kg, mcg/0.3 ml Injection in B03XA03000P5002X A* circumstances: once every two weeks (IV or Prefilled Syringe X i) Patients who require 2 or SC). When the Hb is >11g/dl, A* more subcutaneous administration can be Methoxy Polyethylene B03XA03000P5004X erythropoietin injections per reduced to once monthly X week and need to travel to using the dose equal to twice999 Glycol-epoetin Beta 50 obtain the injections. the previous two weekly mcg/0.3 ml Injection in ii) Patients who are on high dose. ESA-treated patients: doses of subcutaneous 120-360 mcg once monthly Prefilled Syringe erythropoietin injections eg. or 60-180 mcg every two 6000 units or more per time weeks. Methoxy Polyethylene and require more than 1 injection of conventional Non Erythropoiesis1000 Glycol-epoetin Beta 75 erythropoietin per time. Stimulating Agent (ESA)- mcg/0.3 ml Injection in iii) Patients who require 2 or treated patients: 0.6 mcg/kg, more erythropoietin injections once every two weeks (IV or Prefilled Syringe per week and where SC). When the Hb is >11g/dl, compliance is an issue. administration can be reduced to once monthly Treatment of anaemia using the dose equal to twice associated with chronic renal the previous two weekly failure in the following dose. ESA-treated patients : circumstances: 120-360 mcg once monthly i) Patients who require 2 or or 60-180 mcg every two more subcutaneous weeks erythropoietin injections per week and need to travel to Non Erythropoiesis obtain the injections. Stimulating Agent (ESA)- ii) Patients who are on high treated patients: 0.6 mcg/kg, doses of subcutaneous once every two weeks (IV or erythropoietin injections eg. SC). When the Hb is >11g/dl, 6000 units or more per time administration can be and require more than 1 reduced to once monthly injection of conventional using the dose equal to twice erythropoietin per time. the previous two weekly iii) Patients who require 2 or dose. ESA-treated patients : more erythropoietin injections 120-360 mcg once monthly per week and where or 60-180 mcg every two compliance is an issue. weeks Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 orUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 185 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY more erythropoietin injections per week and where compliance is an issue Relief of minor aches and pains of muscles and joints To be massage well to the1001 Methyl Salicylate 25% M02AC00260G5001 C+ associated with simple affected area, 3 - 4 times Ointment XX backache, arthritis and daily. rheumatic conditions. Adult: 250 mg 2 - 3 times daily, gradually increased at intervals of 2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice daily,1002 Methyldopa 250 mg Tablet C02AB01110T1001X B Hypertension increased gradually, X maximum; 2 g daily. Child: Initially, 10 mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least. Adult and children: 1 to 21003 Methylene Blue 1% V03AB17100P3001X B For treatment of idiopathic mg/kg (0.1 to 0.2 mL/kg of a Injection X and drug-induced 1% solution) IV very slowly methaemoglobinemia over 5 minutes. This dosage can be repeated if necessary after one hour. CHILD over 6 years, initially 5 mg 1 - 2 times daily, increased if necessary at weekly intervals by 5 - 10 mg daily to maximum of 60 mg1004 Methylphenidate HCl 10 mg N06BA04110T1001X A Attention deficit hyperactivity daily in divided doses; Tablet X disorder (ADHD) discontinue if no response after 1 month, also suspend periodically to assess child's condition (usually finally discontinued during or after puberty) CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new1005 Methylphenidate HCl 18 mg N06BA04110T5002X A* Attention deficit hyperactivity to methylphenidate: starting Extended-release Tablet X disorder (ADHD) dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month1006 Methylphenidate HCl 20 mg N06BA04110C2003 A* Attention deficit hyperactivity 20 mg once daily to be taken LA Capsule XX disorder (ADHD) in the morning. Dosage beUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 186 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY adjusted in increments to a1007 Methylphenidate HCl 36 mg N06BA04110T5003X A* Attention deficit hyperactivity maximum of 60 mg/day Extended-release Tablet X disorder (ADHD) CHILD over 6 years:1008 Methylphenidate HCl 40mg N06BA04110C2002 A* Attention deficit hyperactivity Individualize dosage, to be LA Capsule XX disorder (ADHD) taken once daily in the morning. Dose may be1009 Methylprednisolone Acetate H02AB04134P3001X A* i) Intramuscular adjusted in increments to a 40mg injection X administration: anti- maximum of 54 mg/day, at inflammatory treatment, weekly interval. Patient new1010 Methylprednisolone Sodium H02AB04520P4001X A treatment of hematological to methylphenidate: starting Succinate 0.5 g Injection X and oncological disorders, dose 18 mg once daily; endocrine disorders adults 18mg or 36mg once ii) Intrasynovial, periarticular, daily. Patient currently using intrabursal or soft tissue methylphenidate: 18 - 36 mg. administration: Indicated as Maximum 54 mg/day. adjunctive therapy for short Discontinue if no response term administration in : after 1 month Synovitis of osteoarthritis, 20 mg once daily to be taken rheumatoid arthritis, acute in the morning. Dosage be and subacute bursitis, acute adjusted in increments to a gouty arthritis, epicondylitis, maximum of 60 mg/day acute nonspecific tenosynovitis, post-traumatic i. Intramuscular route osteoarthritis a) Asthma: may be used in iii) Intralesional use in place of a short burst of oral alopecia areata, discoid steroids in vomiting or non- lupus erythematosus; adherent patients. The keloids, localized recommended dose is 80- hypertrophic, infiltrated 120mg intramuscularly as a inflammatory lesions of one-dose granuloma annulare, lichen b) Adrenogenital syndrome: planus, psoriatic plaques, 40mg every two weeks lichen simplex chronicus c) Rheumatoid arthritis (neurodermatitis) *Restricted (maintenance): 40-120mg to patients experiencing side weekly effects with triamcinolone d) Dermatologic lesions acetonide (acute severe dermatitis, Suppression of inflammatory chronic contact dermatitis, and allergic disorders, seborrheic dermatitis): 40- cerebral oedema, 120mg weekly for 1-4 weeks immunosuppression ii. Intraarticular route treatment of haematological Recommended dose is 4 to 80 milligrams, dependingUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) upon the size of the joint. Injections may be repeated at intervals of 1 to 5 or more weeks in chronic cases iii.Intralesional route 20 to 60 milligrams methylprednisolone acetate injected into the lesion 15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours 187 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY and oncological disorders, treatment of shock states and endocrine disorders Suppression of inflammatory and allergic disorders,1011 Methylprednisolone Sodium H02AB04520P4002X A cerebral oedema, 15 - 30 mg/kg daily. Large Succinate 1 g Injection X immunosuppression doses may be repeated 4 - 6 treatment of haematological hourly for up to 48 hours and oncological disorders, treatment of shock states and endocrine disorders i) CHILD over 5 years: 2.5 - 51012 Metoclopramide HCl 1 A03FA01110L9001X B i) Dyspepsia, flatulence, ml 3 times daily. 3 - 5 years 2 mg/ml Syrup X hiatus hernia, peptic ml 2 - 3 times daily. 1 - 3 ulceration, reflux years: 1 ml 2 - 3 times daily. oesophagitis, gastritis, Under 1 year: 1 ml 2 times duodenitis, cholelithiasis, daily nausea, vomiting ii) Single dose given 10 ii) Promote bowel transit minutes before examination. during diagnostic procedures CHILD over 5 years: 2.5 - 5 ml. Between 3 - 5 years: 2 ml. Under 1 year: 1 ml i) ADULT over 20 years: 10 mg 3 times daily. ADULT i) Dyspepsia, flatulence, between 12 - 20 years: 5 mg hiatus hernia, peptic 3 times daily. CHILD under ulceration, reflux 12 years: 0.12 mg/kg/dose 61013 Metoclopramide HCl 10 mg A03FA01110T1001X B oesophagitis, gastritis, - 12 hourly Tablet X duodenitis, cholelithiasis, ii) Single dose 5 - 10 minutes nausea, vomiting before examination; ADULT ii) Promote bowel transit and CHILD over 15 years: 10 during diagnostic procedures - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly i) ADULT over 20 years: 10 mg 3 times daily. ADULT i) Dyspepsia, flatulence, between 12 - 20 years: 5 mg hiatus hernia, peptic 3 times daily. CHILD under ulceration, reflux 12 years: 0.12 mg/kg/dose 6 Metoclopramide HCl 5 A03FA01110P3001X oesophagitis, gastritis, - 12 hourly1014 mg/ml Injection X B duodenitis, cholelithiasis, ii) Single dose 5 - 10 minutes nausea, vomiting before examination; ADULT ii) Promote bowel transit and CHILD over 15 years: 10 during diagnostic procedures - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly Adult: 5-10 mg daily, increased if necessary to 201015 Metolazone 2.5 mg Tablet C03BA08000T1002X A* Oedema in congestive mg daily. Max: 80 mg in 24 X cardiac failure, nephrotic hr. Elderly: Initially, 2.5 syndrome and impaired renal mg/day or every other day. function Should be taken with food. Take after breakfast.Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 188 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Hypertension: Initially 100 mg1016 Metoprolol Tartrate 100 mg C07AB02123T1002X B Hypertension, angina, to maximum 400 mg daily, Tablet X myocardial infarction, Angina: 50 mg - 100 mg in 2 arrhythmias - 3 times daily. Myocardial infarction: 200 mg daily in1017 Metoprolol Tartrate 50 mg C07AB02123T1001X B Hypertension, angina, divided doses. Arrythmias: 50 Tablet X myocardial infarction, mg - 300 mg in 2 - 3 times arrhythmias daily Hypertension: Initially 100 mg1018 Metronidazole 0.5 g P01AB01000S2001X B Anaerobic infection to maximum 400 mg daily, Suppository X Angina: 50 mg - 100 mg in 2 - 3 times daily. Myocardial1019 Metronidazole 200 mg P01AB01000T1001X B Anaerobic infection infarction: 200 mg daily in Tablet X divided doses. Arrythmias: 50 mg - 300 mg in 2 - 3 timesUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) daily Anaerobic infections Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections. Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections. Prophylaxis of postoperative anaerobic bacterial infections Adult: 1 g 8 hrly starting 2 hr before surgery. Anaerobic bacterial infections Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg 8 hrly. Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. Prophylaxis of postoperative anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be 189 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY limited to a total of 4. Elderly:1020 Metronidazole 200 mg/5 ml P01AB01000L8001X B Anaerobic infection Dose reduction may be Suspension X necessary. Tab: Should be taken with food.1021 Metronidazole 500 mg/100 J01XD01000P9901X A Anaerobic infections ml Injection X CHILD: 7.5 mg/kg 3 times daily for 7 days Treatment of invasive candidiasis, including ADULT: 500 mg IV infusion 8 Micafungin Sodium 50mg hourly. CHILD: 7.5 mg/kg1022 Powder for Solution for J02AX05520P4101X A* candidemia in adults when body weight every 8 hours. X intolerance or resistance to Neonates: 15mg/kg LD, Infusion Amphotericin B or followed by 7.5mg/kg every 12 hourly. 1 month to 18 Fluconazole. years: 7.5mg/kg (maximum 500mg) every 8 hours. i) Fungal infections: Tinea Dosage for adults, pedis, Tinea corporis, Tinea adolescents ≥ 16 years of age and the elderly for the capitis and other treatment of invasive dermatophyte infections candidiasis: - Body weight > 40kg: 100mg/day* - Body1023 Miconazole 2% Cream D01AC02221G1001 B caused by Trichophyton and weight ≤ 40kg: 2mg/kg/day* XX Epidermophyton species *If the patient?s response is ii) Antifungal agent that has inadequate, e.g. persistence of cultures or if clinical been in various candida condition does not improve, the dose may be increased to infections including vaginal 200 mg/day in patients candidiasis weighing > 40kg or 4mg/kg/day in patients1024 Miconazole Nitrate 2% D01AC02221F2001X A Skin infections caused by weighing ≤ 40kg. Treatment Powder X dermatophytes or Candida duration for invasive candidiasis: The treatment duration of candida infection should be a minimum of 14 days. The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and after resolution of clinical signs and symptoms of infection. Apply sparingly and rub gently onto affected area 1-2 times daily continuing for 14 days after lesions have healed Dust powder over infected area 1 - 2 times dailyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 190 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY Usual sedative range 2.5 - Pre-operative sedation, 7.5 mg (about 70 mcg/kg by induction of general IV injection over 30 seconds). Premedication by IM injection1025 Midazolam 5 mg/5 ml N05CD08110P3001 A anaesthesia, premedication 70 - 100 mcg/kg 30 -60 Injection XX and sedation in ICU and minutes before surgery; sedation for minor ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow procedures IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 Pre-operative sedation, mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); induction of general Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.21026 Midazolam 5 mg/ml N05CD08110P3002 A anaesthesia, premedication mg/kg/hour Injection XX and sedation in ICU and Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by sedation for minor IV injection over 30 seconds). procedures Premedication by IM injection 70 - 100 mcg/kg 30 -601027 Midazolam 7.5 mg Tablet N05CD08253T1001 A/KK Pre and post-operative minutes before surgery; XX sedation ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow1028 Minocycline 100 mg J01AA08110C1002X A* As second-line treatment for IV infusion 200 - 300 mcg/kg Capsule X leprosy only (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years1029 Minocycline 50 mg Capsule J01AA08110C1001X A* As second-line treatment for 150 - 200 mcg/kg); X leprosy only Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.21030 Minoxidil 5 mg Tablet C02DC01000T1001 A* Severe hypertension mg/kg/hour XX ADULT: Usually 7.5 - 15 mg at bedtime; or for1031 Mirtazapine 15 mg N06AX11000T4001X A* Major depression premedication, 30 - 60 Orodispersible Tablet X minutes before the procedure. For ELDERLY, debilitated or impaired liver/kidney function: 7.5 mg 100 mg daily 6 - 18 months 100 mg daily 6 - 18 months ADULTS and CHILD above 12 years old: Initially 5 mg daily in single or divided doses (elderly 2.5 mg). May increase by 5 - 10 mg daily at intervals of 3 or more days until optimum control is achieved. Maximum 50 mg daily Initially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommendedUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 191 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1032 Mirtazapine 30 mg N06AX11000T4002X Major depression Initially 15 mg daily at Orodispersible Tablet X A* bedtime increased according A Pterygium, conjunctival to response up to 45 mg daily1033 Mitomycin C 0.002% Eye S01AX00000D2003X A tumour, glaucoma surgery as a single dose at bedtime Drops X A Pterygium, conjunctival or in 2 divided doses. CHILD tumour, glaucoma surgery and ADOLESCENT under 181034 Mitomycin C 0.02% Eye S01AX00000D2001X A* Pterygium, conjunctival years not recommended Drops X tumour, glaucoma surgery 1 - 2 drops several times a A* i) Gastrointestinal, lung, day1035 Mitomycin C 0.04% Eye S01AX00000D2002X breast, cervical cancers 1 - 2 drops several times a Drops X B ii) Bladder tumours day A* iii) Opthalmological 1 - 2 drops several times a1036 Mitomycin-C 10 mg L01DC03000P4001X B conditions: conjunctival day Injection X squamous neoplasia, i) 10 - 20 mg/m2 body squamous cell carcinoma of surface area (BSA) given as1037 Mitoxantrone 20 mg/10ml L01DB07110P3001X conjunctiva, trabeculectomy a single dose through a Injection X chronic lymphocytic running IV infusion repeated leukaemia, chronic every 6 - 8 weeks. The whole Mixed Gas-Gangrene J06AA05000P3001X myelogenous leukaemia. schedule may be repeated1038 Antitoxin 25,000 units/5 ml X Gastric, colorectal, lung depending on the bone cancer marrow Injection N06AG02000T1001 ii) 10 - 40 mg daily or every XX Acute leukaemia, elderly other day (intravesical)1039 Moclobemide 150 mg patients with acute myeloid iii) 0.4 mg topically as a Tablet B05AA06905P9901X leukaemia (AML), single application for X relapsed/resistant acute opthalmological conditions,1040 Modified Fluid Gelatin 4% leukaemia, non-Hodgkin's duration: 1 to 3 minutes Injection lymphoma (NHL) 10 - 12 mg/m2 IV daily for 3 days, in combination with Mixed gas-gangrene other cytotoxic agents. Refer to protocol. CHILD: 5 - 10 Treatment of depressive mg/m2 daily for 3 - 5 days syndrome according to protocol. Treatment of acute For primary volume leukaemia, ADULT: 8 - 12 replacement in mg/m2/day once daily for 4 - hypovolaemia, peri-operative 5 days. CHILD more than 2 stabilization of the circulation, years: same as adult dose. haemodilution, CHILD 2 years: 0.4 extracorporeal circulation mg/kg/day once daily for 3 - 5 days Prophylactic: 25,000 units IM or IV. Therapeutic: Not less than 75,000 units IV Initially 300 mg daily in divided doses. Gradually to increase up to 600 mg daily in divided doses depending on response. Usual range 150 - 600 mg daily. Not recommended in children ADULT 500 - 1500 ml given as IV infusionUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 192 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY (haemodialysis and heart-1041 Modified Polypeptides B05AA10905P9901X lung machine) Administered by intravenous (Polygeline) 3.5% Injection X B For primary volume infusion only. Total dosage A* replacement in and rate of infusion depend1042 Molgramostim 300 mcg L03AA03000P4002X A* hypovolaemia, peri-operative upon the amount of blood Injection X A* stabilization of the circulation, loss and hemodynamic haemodilution, parameters. The usual dose1043 Mometasone Furoate 0.1% D07AC13139G1001 A extracorporeal circulation is 500 to 1000 milliliters (mL), Cream XX (haemodialysis and heart- with total dosage not to lung machine) exceed 2500 mL daily1044 Mometasone Furoate 50 R01AD09139A4101 i) As secondary prophylaxis mcg Aqueous Nasal Spray XX and therapeutic use against SC or IV 250 mcg/m2/day. chemotherapy induced Initiation: 24 to 72 hours after Monobasic Sodium A06AG01162L5001X leucopenia according to chemotherapy. Duration:1045 Phosphate 48%, Dibasic X clinician's discretion Until a clinically adequate ii) Haemopoietic stem cell neutrophil recovery is Sodium Phosphate 18% transplantation (HSCT) achieved Steroid responsive dermatosis and vitiligo. Used Apply thin layer to the where a potent steroid is affected skin areas once required for short duration daily until the lesion heals or not more than 6 weeks for a duration of 3 weeks whichever is Allergic rhinitis sooner.Massage gently and thoroughly until the Bowel cleansing prior to medication disappears. colonoscopy, radiological ADULT and CHILD over 12 examination or bowel surgery years: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved. CHILD 6 - 12 years old: 50 mcg (1 spray) to each nostril once daily 45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. NotUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 193 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY recommended for use in Chronic treatment of asthma children1046 Montelukast Sodium 10 mg R03DC03520T1001 and relief of symptoms of CHILD more than 15 years Tablet XX A/KK seasonal allergic rhinitis for and ADULT: 10 mg daily at bedtime children more than 15 years 12 months - 5 years: 1 and adults packet of 4mg oral granules daily at bedtime Asthmatics, not controlled on high dose inhaled CHILD 6 - 14 years: One 5 mg chewable tablet daily at1047 Montelukast Sodium 4 mg R03DC03520F1001 A* corticosteroids more than bedtime Oral Granules XX 1600 mcg/day and with co- morbid allergic disorders. 5-20 mg or more regularly every 4 hours as needed in Chronic treatment of asthma terminal pain 10 - 60 mg 12 hourly Asthmatics, not controlled on intervals, depend upon the high dose inhaled severity of the pain. Children (more than 1 year of age)1048 Montelukast Sodium 5 mg R03DC03520T2001 A* corticosteroids more than with severe cancer pain: 0.2 - Tablet XX 1600 mcg/day and with co- 0.8mg/kg 12 hourly. 5-10 mg every four hours. morbid allergic disorders. The dose may be increased according to needs Chronic treatment of asthma 15 - 30 mg regularly every 4 hours For use in management of ADULT: 5-20mg SC or IM every 4 hours in terminal pain1049 Morphine HCl 10 mg/5 ml N02AA01110L9901X B moderate to severe pain CHILD: Up to 1 month: 0.15 Solution X especially that associated mg/kg body weight; 1 - 12 with neoplastic disease months: 0.2 mg/kg body weight; 1 - 5 years: 2.5 - 5 Prolonged relief of severe mg ; 6 - 12 years: 5 - 10 mg 15 - 30 mg regularly every 4 Morphine Sulphate 10 mg pain associated with hours Controlled Release Tablet N02AA01183T5001X neoplastic disease; assists in1050 X A procuring sleep where 10 - 60 mg 12 hourly intervals, depend upon the sleeplessness is due to pain severity of the pain or shock 15 - 30 mg regularly every 4 hours1051 Morphine Sulphate 10 mg N02AA01183T6002X A* Relief of moderate to severe 5-10 mg every four hours. Immediate Release Tablet X pain (cancer patient) The dose may be increased according to needs1052 Morphine Sulphate 10 mg N02AA01183S2001X A* Relief of severe chronic pain Suppository X (cancer patient)1053 Morphine Sulphate 10 N02AA01183P3001X B For moderate to severe pain mg/ml Injection X especially that associated with neoplastic disease1054 Morphine Sulphate 20 mg N02AA01183S2002X A* Relief of severe chronic pain Suppository X (cancer patient) Prolonged relief of severe Morphine Sulphate 30 mg N02AA01183T5002X pain associated with Controlled Release Tablet X neoplastic disease; assists in1055 A procuring sleep where sleeplessness is due to pain or shock1056 Morphine Sulphate 30 mg N02AA01183S2003X A* Relief of severe chronic pain Suppository X (cancer patient)1057 Morphine Sulphate 5 mg N02AA01183T6001X A* Relief of moderate to severe Immediate Release Tablet X pain (cancer patient)Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 194 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1058 Morphine Sulphate 60 mg N02AA01183T5003X Prolonged relief of severe 10 - 60 mg 12 hourly Controlled Release Tablet X A pain associated with intervals, depend upon the A* neoplastic disease; assists in severity of the pain. Children1059 Moxifloxacin 0.5% S01AX22110D2001X procuring sleep where (more than 1 year of age) Ophthalmic Solution X A* sleeplessness is due to pain with severe cancer pain: 0.2 - or shock 0.8mg/kg 12 hourly.1060 Moxifloxacin 400 mg J01MA14110P3001X A* CHILD more than 1 year and Injection X Treatment of conjunctivitis ADULT: 1 drop to affected B caused by susceptible eye(s) 3 times daily for 71061 Moxifloxacin 400mg Tablet J01MA14110T1001X B organism days X C+1062 Multivitamin Drops B Second line therapy for IV or Oral: 400 mg once1063 Multivitamin Injection A11BA00901D5001X A Severe Community Acquired daily. The recommended1064 Multivitamin Syrup X A Pneumonia (CAP) patients total treatment duration for1065 Multivitamin Tablet with co-morbidity or with sequential administration1066 Mupirocin 2% Cream A11BA00901P3001X recent antibiotic therapy, (intravenous followed by oral1067 Mupirocin 2% Ointment X suspected infections of therapy) is 7 to 14 days resistant pathogens including A11BA00901L9001X Streptococcus pneumoniae, IV or Oral: 400 mg once X Haemophilus influenzae & daily. The recommended Mycoplasma pneumoniae. total treatment duration for A11BA00901T1001X Second line therapy for sequential administration X Severe Community Acquired (intravenous followed by oral Pneumonia (CAP) patients therapy) is 7 to 14 days D06AX09000G1001 with co-morbidity or with XX recent antibiotic therapy, INFANT less than 1 year: 1 suspected infections of ml daily D06AX09000G5001 resistant pathogens including Initially 2 - 4 pairs IV 4 - 8 XX Streptococcus pneumoniae, hourly, reducing to 1 pair IV Haemophilus influenzae & daily. For less serious cases, Mycoplasma pneumoniae. 1 pair IV 1 - 2 times daily or For prevention and treatment based on individual of vitamin deficiencies requirements CHILD 5 ml daily or based on For prevention and treatment manufacturer of vitamin deficiencies 1 - 2 tablets daily or based on individual requirements For prevention and treatment of vitamin deficiencies Adults and child over 1 year, For prevention and treatment apply up to 3 times daily for of vitamin deficiencies up to 10 days Skin infection by Staphylococcus aureus ADULT and CHILD: Apply up (including MRSA), to three times daily for up to Staphylococcus epidermidis 10 days and beta-haemolytic streptococcus For MRSA infections onlyUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 195 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY1068 Mycophenolate Mofetil 250 L04AA06236C1001X i) Prophylaxis of acute organ i) Renal transplant rejection: mg Capsule X A* rejection in patients receiving ADULT: 1 g twice daily. allogenic renal, cardiac and CHILD (3 months and older):1069 Mycophenolate Mofetil 500 L04AA06236T1002X A* hepatic transplant 600 mg/m(2)/dose, twice mg tablet X ii) Used with steroids for daily; maximum daily dose, 2 A* induction and maintenance of g/10 mL. Cardiac transplant1070 Mycophenolate Sodium L04AA06520T1001X A* severe lupus nephritis rejection: 1.5 g twice daily. 180mg Tablet X B resistant or intolerant to Hepatic transplant rejection: B cyclophosphamide therapy 1.5 g twice daily1071 Mycophenolate Sodium L04AA06520T1002X B ii) Induction phase: 2 - 3 360mg Tablet X i) Prophylaxis of acute organ g/day for up to 6 months. rejection in patients receiving Maintenance phase: dose1072 Nalbuphine HCl 10 mg/ml N02AF02110P3001X allogenic renal, cardiac and gradually tapers to 1 g/day Injection X hepatic transplant i) Renal transplant rejection: ii) Used with steroids for ADULT: 1 g twice daily.1073 Naloxone HCl 0.02 mg/ml V03AB15110P3001X induction and maintenance of CHILD (3 months and older): Injection X severe lupus nephritis 600 mg/m(2)/dose, twice resistant or intolerant to daily; maximum daily dose, 21074 Naloxone HCl 0.4 mg/ml V03AB15110P3002X cyclophosphamide therapy g/10 mL. Cardiac transplant Injection X rejection: 1.5 g twice daily. Prophylaxis of acute Hepatic transplant rejection: transplant rejection in adult 1.5 g twice daily patients receiving allogenic ii) Induction phase: 2 - 3 renal transplant in g/day for up to 6 months. combination with ciclosporin Maintenance phase: dose and corticosteroids gradually tapers to 1 g/day Prophylaxis of acute transplant rejection in adult 720 mg twice daily patients receiving allogenic renal transplant in 720 mg twice daily combination with ciclosporin and corticosteroids 10 - 20 mg SC, IM or IV Perioperative analgesia, for every 3 - 6 hours relief of moderate to severe pain 0.005 - 0.01 mg/kg body For the complete/partial weight repeated at intervals reversal of narcotic of 2 - 3 minutes according to depression including the patient's needs by IM, IV respiratory depression or SC induced by opioids such as natural and synthetic Initially 0.4 - 2 mg IV narcotics. Diagnosis of repeated at intervals of 2 - 3 suspected acute opioids minutes according to overdosage patient's needs For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis ofUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 196 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY suspected acute opioids overdosage Initial 25 mg may be increased to 50 mg.1075 Naltrexone HCl 50 mg N07BB04110T1001X A Adjunct in relapse prevention Maintenance: 350 mg Tablet X treatment in detoxified weekly; administered as 50 formerly opioid-dependant mg daily. Dosing interval may patients be lengthened to improve compliance; 100 mg on alternate days or 150 mg every third day ADULT: 25 - 50 mg every 31076 Nandrolone Decanoate 25 A14AB01135P3001X A Anabolic therapy weeks by IM. CHILD over 2 mg/ml Injection X years: 25 - 50 mg every 3 to 4 weeks1077 Naproxen 250 mg Tablet M01AE02000T1001 A/KK i) Rheumatic arthritis, i) 0.5 - 1 g daily in 2 divided XX osteoarthritis and ankylosing doses spondylitis ii) 750 mg initially then 250 ii) Acute gout mg 8 hourly iii) Muscular skeletal iii) 500 mg initially then 250 disorder, dysmenorrhoea mg every 6 - 8 hour as required i) Rheumatic arthritis, osteoarthritis and alkylosing1078 Naproxen Sodium 275 mg M01AE02520T1001 A spondylitis 550 mg- 1100 mg in two Tablet XX ii) Acute gout divided doses iii) Muscular skeletal disorder and dysmenorrhoea1079 Neomycin 0.5% Cream D06AX04256G1001 B Infections of the skin due to Apply sparingly to affected XX susceptible organisms area up to 3 times daily (For short term use, 1 - 2 weeks) Treatment of the following conditions where bacterial1080 Neomycin 0.5% in D07CC01947G1001 B infection is present or likely to Apply sparingly to affected Betamethasone 17-Valerate XX occur: eczemas, prurigo area 2 - 3 times daily. (May 0.01% Cream nodularis, psoriasis cause sensitisation to (excluding widespread neomycin. Use with caution) plaque psoriasis), neurodermatoses, anal and genital intertrigo Treatment of the following conditions where bacterial1081 Neomycin 0.5% in D07CC01947G5001 B infection is present or likely to Apply sparingly to affected Betamethasone 17-Valerate XX occur: eczemas, prurigo area 2 to 3 times daily. (May 0.01% Ointment nodularis, psoriasis cause sensitisation to (excluding widespread Neomycin. Use with caution) plaque psoriasis), neurodermatoses, anal and genital intertrigo Treatment of the following conditions where bacterial1082 Neomycin 0.5% in D07CC01947G1002 A infection is present or likely to Apply sparingly to affected Betamethasone 17-Valerate XX occur: eczemas, prurigo area 2 - 3 times daily (May 0.1% Cream nodularis, psoriasis cause sensitisation to (excluding widespread neomycin. Use with caution) plaque psoriasis),Updated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 197 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY neurodermatoses, anal and genital intertrigo Treatment of the following conditions where bacterial1083 Neomycin 0.5% in D07CC01947G5002 A infection is present or likely to Apply sparingly to affected Betamethasone 17-Valerate XX occur: eczemas, prurigo area 2 to 3 times daily. (May 0.1% Ointment nodularis, psoriasis cause sensitisation to (excluding widespread neomycin. Use with caution) plaque psoriasis), neurodermatoses, anal and genital intertrigo1084 Neomycin 0.5% Ointment D06AX04256G5001 B Infections of the skin due to Apply sparingly to affected XX susceptible organisms area up to 3 times daily (For short term use, 1- 2 weeks)1085 Neomycin with Polymyxin B S01AA30990D2001X A Eye infections that require a 1 - 2 drops in the affected Sulphate and Gramicidin X broad spectrum antibiotic eye 2 - 4 times daily. In Eye Drops severe infections : 1 - 2 drops every 15 - 30 minutes i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg. CHILD: 200 - 500 Neostigmine N07AA01183P3002X B i) Myasthenia gravis mcg at suitable intervals1086 Methylsulphate 2.5 mg/ml X ii) Reversal of non- throughout the day. depolarising neuromuscular NEONATE: 50 - 250 mcg Injection blockade every 4 hours ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg) after or with atropine sulphate 0.6 - 1.2 mg ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided Netilmicin Sulphate 100 J01GB07183P3002X doses for 7 - 14 days. mg/2 ml Injection X Maximum: 7.5 mg/kg/day.1087 A Systemic infections CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days.1088 Netilmicin Sulphate 150 J01GB07183P3003X A Systemic infections Maximum: 7.5 mg/kg/day. mg/2 ml Injection X CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Netilmicin Sulphate 50 mg/2 J01GB07183P3001X Maximum: 7.5 mg/kg/day.1089 ml Injection X A Systemic infections CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/dayUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 198 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE1090 Nevirapine 200 mg Tablet J05AG01000T1001X CATEGORY Treatment of HIV-1 infection Combined with other1091 Nevirapine 50mg/5ml Oral X A/KK in combination with other antiretrovirals: 200 mg once Suspension antiretroviral agents daily for the 1st 14 days; up J05AG01000L8001X A/KK to 200 mg twice daily if rash1092 Nicotine 10 mg/ 16 hour X Treatment of HIV-1 infection does not develop. Re- Transdermal Patch A/KK in combination with other introduce at a lower dose for N07BA01000M7005 A/KK antiretroviral agents the 1st 14 days if treatment is1093 Nicotine 14mg/24 hour XX A/KK interrupted for >7 days, Transdermal Patch For the treatment of tobacco necessitate reintroduction at N07BA01000M7002 dependence by relieving a lower dose for the first 141094 Nicotine 15 mg/ 16 hour XX nicotine withdrawal days. Transdermal Patch symptoms, thereby The total daily dose should N07BA01000M7006 facilitating smoking cessation not exceed 400mg. XX in smokers motivated to quit. Nevirapine may be dosed in paediatric patients either by For the treatment of tobacco body surface area (BSA) or dependence by relieving by body weight. nicotine withdrawal i) By BSA using the Mosteller symptoms, thereby formula: the recommended facilitating smoking cessation oral dose for paediatric in smokers motivated to quit. patients of all ages is 150 For the treatment of tobacco mg/m2 once daily for 2 dependence by relieving weeks followed by 150 nicotine withdrawal mg/m2 twice daily thereafter. symptoms, thereby ii) By body weight: -<8 years facilitating smoking cessation of age: 4 mg/kg once daily for in smokers motivated to quit. 2 weeks followed by 7 mg/kg twice daily thereafter. -≥8 years: 4 mg/kg once daily for 2 weeks followed by 4 mg/kg twice daily thereafter. Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months. Apply 1 patch daily for 24 hours as in the product leaflet Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mgUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 199 / 314

MINISTRY OF HEALTH MEDICINES FORMULARY (MARCH 2016)NO. GENERIC NAME MDC PRESCRIBER INDICATION(S) DOSAGE CATEGORY patch daily for another 2 For the treatment of tobacco weeks. Apply to dry non-hairy skin site. Application limited dependence by relieving to 16 hours in a 24-hr period in each case. Review at 31095 Nicotine 2 mg Gum N07BA01000M9901 A/KK nicotine withdrawal months. XX symptoms, thereby Smokes ≤ 20 sticks/day, facilitating smoking cessation chew 2mg gum. Smokes ≥ 20 sticks/day, chew 4 mg in smokers motivated to quit. gum. (MAX 24 pieces /day for up to 12 week.) For the treatment of tobacco Apply 1 patch daily for 24 dependence by relieving hours as in the product leaflet.1096 Nicotine 21mg/24 hour N07BA01000M7003 A/KK nicotine withdrawal Transdermal Patch XX symptoms, thereby Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ facilitating smoking cessation 20 sticks/day, chew 4 mg in smokers motivated to quit. gum. (MAX 24 pieces /day for up to 12 week.) For the treatment of tobacco Adult over 18 years old: 15 N07BA01000M9902 dependence by relieving mg patch on waking (usually XX nicotine withdrawal in the morning) and remove1097 Nicotine 4 mg Gum A/KK symptoms, thereby 16 hours later (usually at bedtime) for 8 weeks, then facilitating smoking cessation 10 mg patch daily for 2 in smokers motivated to quit. weeks followed by one 5 mg patch daily for another 2 For the treatment of tobacco weeks. Apply to dry non-hairy dependence by relieving skin site. Application limited to 16 hours in a 24-hr period1098 Nicotine 5 mg/ 16 hour N07BA01000M7004 A/KK nicotine withdrawal in each case. Review at 3 Transdermal Patch XX symptoms, thereby months. facilitating smoking cessation Apply 1 patch daily for 24 in smokers motivated to quit. hours as in the product leaflet. For the treatment of tobacco Prophylactic: 15 - 30 mg dependence by relieving daily. Therapeutic: 50 - 250 mg daily. Maximum single1099 Nicotine 7mg/24 hour N07BA01000M7001 A/KK nicotine withdrawal dose: 200 mg. Maximum Transdermal Patch XX symptoms, thereby dose in 24 hours: 800 mg 100 - 200 mg 3 times daily, facilitating smoking cessation gradually increased over 2 - in smokers motivated to quit. 4 weeks to 1 - 2 g 3 times daily with or after meals.1100 Nicotinic Acid 50 mg Tablet A11HA01000T1001X B For prophylaxis and CHILD: 100 - 250 mg/day in X treatment of Vitamin B3 3 divided doses with meals, deficiency increase 100 mg/day weekly or 250 mg/day every 2 - 31101 Nicotinic Acid 500 mg C10AD02000T1001X B Hyperlipidaemia Tablet XUpdated until MOH Medicines Formulary Review Panel Meeting 1/2016 (March 2016) 200 / 314